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ABSTRACT
PREVENTION AND TREATMENT OF LUNG CANCER
BY GREEN TEA POLYPHENOLS

Pengxiao Cao

June 6, 2011

Green tea polyphenols (GTPs) are gaining increasing attention because of their
potential anti-tumor effects. However, poor oral bioavailability limits their efficacy in
vivo. In this dissertation, two hypotheses were tested: 1) GTPs administered systemically
by a sustained release system will circumvent the problem of limited bioavailability and
lower the effective dose compared to the traditional oral route, and 2) adjuvant treatment
of GTPs with a standard chemotherapeutic agent (e.g. cisplatin) will enhance efficacy of
the therapeutic agent.
In our lab, a polymeric implant delivery system was developed, in which GTPs
were uniformly embedded within a polycaprolactone matrix to provide sustained release
of GTPs. The release profile of GTP implants was further investigated both in vitro and
in vivo.
To test the first hypothesis, polyphenon E (poly E), a standardized green tea extract,
was administered by PCL implants grafted subcutaneously or via the drinking water to

v

SID rats. The animals were challenged by benzo[a]pyrene (BP) Via subcutaneous
implant. Results showed a significant reduction of BP-induced DNA adducts

III

the

implant group; however, only a modest but insignificant reduction occurred

III

the

drinking water group. Notably, the total dose of poly E administered was> lOO-fold lower
in the implant group. Analysis of selected phase I, phase II, and DNA repair enzymes at
the mRNA, protein levels and enzymatic activity showed no significant modulation by
poly E. The effect of poly E on DNA adduct formation was presumably due to
scavenging of the reactive intermediates of BP by GTPs, which was illustrated by other
experiments in this dissertation.
To test the second hypothesis, the combined effects of the GTPs, anthocyanidins
and cisplatin on the growth of lung cancer H1299 cells in cell culture and also a xenograft
nude mouse model were investigated. In both studies, combination of GTPsanthocyanidins with cisplatin exerted a more dramatic anti-cancer effect. However,
systemic toxicity was found in the animals receiving the combination treatment. Possible
mechanism of action was investigated.
Together, these data demonstrated that sustained systemic delivery of poly E lower
the effective dose by overcoming oral bioavailability and combination of GTPsanthocyanidins and suboptimal doses of cisplatin may be effective in neo-adjuvant
chemotherapy.
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CHAPTER I: GENERAL INTRODUCTION

Epidemiology of lung cancer

Data from the National Cancer Institute, the Center for Disease Control and
Prevention, the North American Association of Central Cancer Registries and the
National Center for Health Statistics indicate that, in the United States, lung cancer is the
second most common cancer diagnosed in 2010, only less than prostate cancer in men
and breast cancer in women. Numerically, this translates to 116,750 males and 105,770
females diagnosed with lung cancer in 2010, which accounts for 15% and 14% of all the
cancer types respectively (1). Moreover, lung cancer also accounts for the highest cancerrelated death rate, 29% death in men and 26% in women, which corresponds to the death
of 86,220 male patients and 71,080 female patients (1).
Worldwide estimates of the incidence and mortality of lung cancer provided by the
International Agency for Research on Cancer (IARC) indicated that lung cancer
contributed to 13% of the total cancer cases and 18% of cancer-related deaths in 2008,
which represents 1.6 and 1.4 million cases respectively. Worldwide, lung cancer is the
leading cancer type diagnosed in males, accounting for 17% of the total new cancer cases
and 23% of the cancer-related deaths. In females, it's the fourth most commonly
diagnosed cancer only less than breast, colon & rectum and cervical cancers, and the
second leading cause of cancer-related deaths (2).

Treatment of lung cancer

The treatment regimens for lung cancer are based on the type and stage of lung
cancer and the patients' overall health. To date, standard treatment options include
surgical resection, chemotherapy and radiation therapy with chemotherapy comprising
the backbone of the treatment strategies. Despite the development of various
chemotherapeutic agents in 1980s and 1990s, platinum containing therapy was the most
commonly selected regimen largely a result of its efficacy, yielding a responsive rate of
30-40% and a median survival time estimated to be one year for patients in advanced
stages (3).
The standard chemotherapeutic treatments discussed above have a somewhat non
selective mechanism, i.e. both cancer and non cancer cells can be affected by these
treatments. However, the recent appearance of molecular target therapy has provided an
opportunity to more selectively target cancer cells. Cancer cells acquire some common
phenotypes including unlimited proliferation, resistance to apoptotic signals and
metastasis through the accumulation of a variety of genetic and epigenetic changes.
Advancements in molecular biology and biochemistry make it possible to identify and
target these molecular mechanisms. One such promising class of therapeutics is inhibitors
of epidermal growth factor receptor (EGFR) such as gefitinib and erlotinub which have
been found to exert dramatic clinical effects, resulting in a prolonged (approximately 4
months) progression-free survival time of patients with lung cancer compared with
patients treated with platinum doublet therapy. Several other molecular-targeting drugs
have also demonstrated significant promise towards lung cancer treatment or are
currently under investigation in clinical trials including the anti-angiogenetic drug
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bevacizumab, the anti-epidermal growth factor receptor antibody cetuximab and theantivascular endothelial growth factor antibody bevacizumab (4, 5).

Lung cancer prognosis

Despite the progress in cancer research and cancer treatment strategies, the
prognosis of lung cancer remains relatively poor as reflected in the mortality rate. In
developed countries, the overall 5-year relative survival rate for lung cancer patients was
12-18%, in comparison with other most commonly diagnosed malignancies including 7389% for breast cancer, 50-99% for prostate cancer and 43-63% for colorectal cancer (6).
Furthermore, this prognosis has improved only marginally over the last few decades.
Clearly, more effective therapeutic strategies are urgently needed.

Risk factors for lung cancer

The majority of lung cancers have been attributed to environmental factors. The
incidence of lung cancer strongly correlates with cigarette smoking, with 90% of lung
cancers associated with tobacco use (7). Kentucky has the highest adult smoking rates in
the U.S., with 30% or more of the population identified as smokers; a number that greatly
surpasses other states (8). Not surprisingly, lung cancer incidence and mortality rates in
Kentucky are among the highest in United States (9).
Although tobacco smoke contains more than 5,000 chemicals, several dozens of
them are carcinogenic, mutagenic or tumor promoters. Two classes of compounds have
been identified and most investigated as animal carcinogens, namely nitrosamines and
polycyclic aromatic hydrocarbons (PARs) (l0, 11).
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Another significant source of these environmental carcinogens, predominantly
found in developing countries, is the emission from coal combustion associated with
cooking and heating, particularly in rural areas of China. These combustion processes
result in higher PAH levels in air indoor and outdoor and have been associated with an
elevated lung cancer risk to populations in these regions (12, 13).

Benzo[a]pyrene and carcinogenesis

Benzo[a]pyrene (BP) is a model PAH, and also one of the most potent
environmental carcinogens found ubiquitously in tobacco smoke, automobile exhaust
emissions and grilled foods (14, 15).

Numerous studies have demonstrated the

association of BP exposure and induction of carcinogensis in many organs including
lung, skin, mammary gland and others (16-18).
Enzymatic activation is needed before BP can be metabolized to its

ultimate

carcinogenic metabolite, anti-benzo[ a ]pyrene-7 ,8-diol-9, lO-epoxide (anti- BPDE) and
other potentially carcinogenic and/or mutagenic agents. Certain types of cytochrome
P450s (CYPs) found in the subcellular microsomal fraction, especially CYPIAl,
CYPIB 1 are involved in this process (19). Anti-BPDE exerts its carcinogenic activity by
alkylating nucleosides in DNA molecules at the structurally named bay region of the
anti-BPDE moiety. The reaction predominates with the purine bases, particularly

deoxyguanosine in DNA (20). As a result, both bulky stable and depurinating DNA
adducts are formed (21, 22). Insufficient removal of stable DNA adducts prior to
replication can create mutational hot spots in the gene which may result in deactivation of
tumor suppressor genes or activation of oncogenes leading to tumor initiation (23-26).
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Need for prevention

In the United States, annual age-adjusted incidence rates for lung and bronchus
cancer has reportedly decreased from 1984 through 2006 in males. However, this
observation has not been found in females. One of the most significant reasons for this
disparity is believed to be the historical differences in cigarette smoking between men
and women. Cigarette smoking by women appeared to peak approximately 20 years later
than men (1). This peak pattern coupled with widespread and significant lung cancer
incidence, substantial mortality and poor prognosis strongly suggest the importance of
developing prevention strategies, including tobacco control, in the control of lung cancer
development. As previously discussed, current treatment strategies for lung cancer only
have limited effects in improving the prognosis of lung cancer patients. Therefore, cancer
prevention should be put in a more prominent position which could dramatically
influence the incidence and death rate of lung cancer. Further, for high-risk individuals
including heavy smokers (e.g., people with 50-100 pack-year history) and long term
workers expose to smoke or fumes occupationally, specific chemopreventive intervention
may be necessary.

Natural products with chemopreventive/chemotherapeutic activity

One promising pathway towards preventing cancers including those of the lung is
the use of natural products. Natural products are part of human lives historically and
currently. Many of them have been found to bear medicinal functions. Studies have
demonstrated the chemopreventive/chemotherapeutic effects of many natural compounds,
e.g. green tea and tea catechins, curcumin in the yellow spice turmeric, resveratrol in the
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skin of red grapes, isoflavones and soy preparations from beans, tanshinone in the
Chinese folklore tanshen, the red carotenoid pigment lycopene in tomatoes, water melon,
etc., quercetin from apples and other fruits, etc. These compounds are able to inhibit
tumor cell proliferation, induce cell apoptosis in cell culture and inhibit the formation and
development of tumors at various stages in animal studies, suggesting their potential use
in cancer patients or cancer survivors (27-32). For example, pomegranate fruit extracts
inhibited the growth of colon, prostate and lung cancer cells in culture and also in animal
models (28). Apple juice and apple extracts can modulate signaling transduction
pathways and prevent skin, mammary and colon carcinogenesis (30).
Some natural compounds have been tested or are under investigation in clinical
trials with promising results. For example, administration of green tea catechins was
found to be very effective for treating premalignant lesions of prostate in a doubleblinded, placebo-controlled study. The incidence of prostate cancer in treatment group is
3% verse 30% in the placebo group (33). In another clinical trial, the combination of
curcumin and quercetin reduced the size and number of intestinal adenomas in patients
with familial adenomatous polyposis (34).
Other possible applications of these natural compounds include, but are not limited
to, use as adjuvants to standard chemotherapeutic agents for the purpose of decreasing
toxicity of standard chemotherapeutic agents or increasing efficacy, which will be
discussed in the section of "dilemma of chemotherapy" in this chapter (35-39).

Green tea polyphenols' antitumor effects and safety profile
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Green tea is one of the most popular drinks in the world. Studies are now
suggesting that green tea has many health benefits, which are attributed to its bioactive
components, including epicatechin (EC), epigallocatechin (EGC), epicatechin gallate
(ECG) and epigallocatechin gallate (EGCG) (40, 41).

GTPs are highly potent

antioxidants and may help prevent atherosclerosis, particularly coronary artery disease
(42, 43). Also, using a murine model, GTPs have been found to have beneficial effects in
the treatment of neurodegenerative diseases (44).
More recently, green tea has been attracting attention because of its possible
application in cancer prevention. The anticarcinogenic effects of GTPs have been tested
using a variety of cancer cell lines in vitro (45-49). More importantly, in the majority, but
not all, of published animal studies, green tea preparations were found to decrease lung
tumor incidence and tumor multiplicity in chemically-induced lung tumor models,
including both PAHs (e.g., BP) and nitrosamines (e.g., N-nitrosodiethylamine (NDEA)
and 4-(methylnitrosamino)- 1 -(3-pyridyl)- 1- butanone (NNK) (41, 50-54). Green tea
preparations were found to be effective when administered to mice either during or after
carcinogen exposure to reduce tumor incidence and multiplicity (50, 51). Studies also
showed that green tea extracts are effective in decreasing tumor multiplicity and tumor
incidence by approximately 60% and 25% in animal models of esophageal and gastric
carcinogesis (41).These results suggest the anti-tumor potential of GTPs.
GTPs are usually not perceived as "medicine" by people who drink tea or even
those who don't drink tea. One reason is because of the level of safety of GTPs. The
adverse events in humans are mild after daily administration of 800 mg EGCG for four
weeks, which are no different with those reported in the placebo group. Additionally,
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repeated administration of GTPs has no significant impact on blood counts and blood
chemistry profiles (55). The systemic review performed by US Pharmacopeia (USP)
Dietary Supplement Information Expert Committee (DSI EC) showed that no significant
safety issues were found when dietary supplement products containing green tea extracts
are used and formulated (56).

Mechanisms of action of green tea polyphenols
The possible mechanisms of action of green tea catechins have been extensively
studied in vitro. GTPs were found to induce apoptosis in cancer cells and inhibit the
proliferation of a variety of cancer cells types in vitro, including lung cancer cells (4549). GTPs have also been shown to inhibit epidermal growth factor (EGF), hepatocyte
growth factor (HGF) and fibroblast growth factor 2 (FGF2) dependent signaling
pathways, and interfere with enzyme activities of JUK, JUN, MEKl, MEK2, EKl, EK2,
CDK2 (57). They are also highly potent antioxidants (58). In the presence of transition
metal ions or alkalis, GTPs can generate reactive oxygen species, including hydrogen
peroxides which are believed to help to kill cancer cells (59, 60). However, the broad in
vitro and in vivo anti-cancer effects of GTPs are not attributed to a single mechanism but
most likely are due to a combination of mechanisms that results in the efficacy of GTPs.
The translation of mechanisms of action found from in vitro studies to in vivo studies,
however, remains inconclusive.

Inconsistent data
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Although GTPs have exhibited chemopreventive effects in most published animal
studies, these data have been somewhat inconsistent. In some studies, GTPs failed to
show beneficial effects in the prevention of lung tumorgenesis in tobacco smoke-induced
lung tumor models in All mice (61, 62). It is also reasonable to speculate that even more
studies have not been published due to negative results. Furthermore, reviews of
epidemiological and clinical studies indicate only a marginal beneficial association
between green tea consumption and lung cancer risk (63, 64). Similarly, green tea did not
show definitive effects on other cancer types, including gastric, colorectal and breast
cancer (65-69).

Bioavailability of green tea polyphenols
One likely reason for the inconsistency of these studies with GTPs is their lack of
bioavailability following oral exposure, which ultimately results in low blood levels of
the bioactive components (70-74). EGCG and ECG are the most abundant and active
compounds in GTPs. However, only about 0.1 % of EGCG was bioavailable in rats
following intragastric (i. g.) administration, resulting in a maximum plasma concentration
(Cmax) of EGCG only at ng/ml level (13.2 - 16.3 ng/ml) (72). Bioavailability for ECG
ranged from 1 to 3.3% in rats following oral administration. Again, the Cmax of ECG
was also only determined to be at the ng/ml level (49.6 - 464.0 ng/ml) (73). In clinical
studies, the blood levels of EGCG were found to range from pg/ml to ng/ml, even after
large doses (75, 76). The lack of bioavailability indicated from these studies coupled with
the demonstrable efficacy, low toxicity and known chemoprotective mechanisms of
GTPs in several animal studies strongly suggests that these agents may exhibit greater
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efficacy under conditions in which bioavailability can be increased by avoiding oral
dosing routes.

The dilemma of chemotherapy
The basic principle of chemotherapy is to kill as many tumor cells as possible by
treatment with chemicals in order to minimize the tumor burden. However, the majority
of these drugs also affect normal cells such that each drug has its maximum tolerable
dosage considering the toxicity and side effects. In practice, usually two or more
chemotherapeutic agents with a lower dose in combination are needed in order to
maximize efficacies and minimize toxicities and side effects (77, 78). The principle for
combination of these therapeutics is to choose drugs with differing molecular targets,
mechanisms of action and side effects (78). The most commonly used chemotherapeutic
drugs in lung cancer treatment and their mechanisms of action and molecular targets are
as follows: cisplatin, carboplatin (crosslinking with DNA) (79, 80); paclitaxel, docetaxel
(anti-microtubule) (81, 82); doxorubicin (interact with DNA by intercalation) (83);
gemcitabin (nucleoside analog, anti-metabolite) (84); vinorelbin (anti-mitotic, antimicrotubule) (85); etoposide (topoisomerase II inhibitor) (86); irinotecan and topotecan
(topoisomerase I inhibitor) (87, 88). As noted previously, GTPs bear many mechanisms
of action which are different from traditional chemotherapeutic agents, such as induction
of ROS production and interference with signal transduction (57). Clearly, the molecular
targets of GTPs are different from the chemotherapeutic drugs mentioned above (57).
Additionally, as noted previously, GTPs are relatively safe as phytochemicals (56).
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Therefore, it's reasonable to hypothesize that GTPs can be used as a neo-adjuvant
treatment in the prevention and treatment of lung cancer.

In limited studies, it has been shown that green tea catechins enhanced the effect of
gemcitabin, dacarbazine, doxorubicin or taxol in different cancer cell lines both in vitro
and in xenograft animal models (37, 89-91). The combination of EGCG or ECG with
doxorubicin increased intracellular doxorubicin accumulation in the chemoresistant
hepatocellular carcinoma cell line BEL-7404IDOX,

significantly inhibited cell

proliferation in vitro, and hepatoma growth in a xenograft mouse model (37). EGCG was
found to be able to sensitize human cholangiocarcinoma cell line Mz-ChA-l to
gemcitabine-induced apoptosis in vitro and in vivo (89). Similarly, the enhanced effects
of EGCG and dacarbazine on B16-F3m melanoma cells and those of EGCG and
paclitaxel on 4Tl breast cancinoma were observed (90, 91). No chemosenstizing effect of
GTPs seem to have been reported in a lung cancer cell line and/or lung cancer animal
model.

Hypotheses
My first hypothesis is that GTPs administered systemically, by a sustained-release
system, will circumvent the problem of limited bioavailability and lower the effective
dose compared to the traditional oral route. We have developed a novel delivery system
in which GTPs are uniformly embedded with a polymer matrix to provide sustained
release of GTPs. In the following studies, I will test this delivery system both in vitro and
in vivo, and eventually test the hypothesis.
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My second hypothesis is that adjuvant treatment of GTPs with a standard cancer
chemotherapeutic agent (e.g. cisplatin) will enhance efficacy of the drug and lower its
toxicity.

Specific Aims
The following specific aims will be pursued to achieve my goals:
Aim l: To characterize and optimize the delivery of green tea polyphenols by
polymeric implants. Polymer formulations will be developed using biodegradable
polymers and GTPs and tested to determine the rate of release of GTPs in vitro and in
VIVO.

Aim 2: To determine the efficacy of green tea polyphenols against carcinogeninduced DNA adducts in vitro. Microsomal and microsome-free systems will be
employed to determine the relative efficacy of green tea catechins (EC, EGC, ECG and
EGCG) to inhibit DNA adducts induced by BP as measured by 32P-postlabeling.
Spectroscopic methods will be used to determine scavenging of electrophilic metabolites
of BP by GTPs.
Aim 3: To determine short-term chemoprotective effects of green tea polyphenols
administered by subcutaneous polymeric implants or orally in vivo. Rats will be treated
with BP by subcutaneous implants alone or with BP co-administered with GTPs by
polymeric implants or by oral. Animals will be euthanized at different intervals to
determine the effects of GTPs on tissue BP-DNA adducts as measured by 32 p _
postlabeling. Effects on selected phase I, phase II enzymes and other related enzymes
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will be measured by quantitative RT-PCR and protein levels by Western blotting. The
plasma and tissue levels of the GTPs will be determined by LC/MS.
Aim 4: To determine efficacy and potential mechanisms of adjuvant treatment of
green tea polyphenols and a standard chemotherapeutic drug on lung cancer development
using rodent models. Human lung cancer cell lines (H1299 and A549) will be used in cell
culture studies first to test whether EGCG can enhance the effect of a standard
chemotherapeutic drug. Nude mice will then be injected with human lung cancer cells
and then subcutaneously treated with GTPs and the chemotherapeutic agent individually
and as an adjuvant. Efficacy of the various treatments will be determined by measuring
tumor indices and modulation of selected biomarkers.

Significance of the studies
Data resulting from these studies will identify the potential role of GTPs in lung
cancer intervention and the possible mechanisms by which these agents mediate the
carcinogenic process. Importantly, these studies provide an alternative approach to oral
exposure that can circumvent bioavailability problems following oral administration of
prospective chemopreventive or chemotherapeutic agents as well as lower the effective
dose compared with the traditional oral route. Furthermore, adjuvant treatment of GTPs
and a chemotherapeutic drug may increase the drug's efficacy by lowering its effective
dose, reducing its toxicity and/or circumventing drug resistance. Future prospects of
positive results of this proposed work include clinical trials using polymeric devices
trapped with GTPs

in the treatment of human lung cancer with standard

chemotherapeutic drugs.
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CHAPTER II: CHARACTERIZATION AND OPTIMIZATION OF THE
DELIVERY OF GREEN TEA POL YPHENOLS BY POLYMERIC IMPLANTS

Introduction:
The concept of drug delivery by implants has been applied in a clinical setting for
many years. One of the most successful applications of drug delivery by this method to
date is sub-dermal contraceptive implants. These implant types have been accepted by
millions of women over the past 30 years due to their long lasting efficacy and moderate
side effects. However, insertion and removal of the implants has proven to be the greatest
barrier to their clinical applications (92). One method to eliminate the necessity of
removal of these implants is to use biodegradable materials. This concept has been tested
in animal models in recent studies to deliver sex-related hormones and has been proven to
be very promising (93, 94). However, biodegradable materials for sub-dermal delivery
have not been tested to deliver chemopreventive agents.
The exceptionally low bioavailability of epigallocatechin gallate (EGCG) and
epicatechin gallate (ECG), which are also the most active components of green tea
polyphenols (GTPs), following oral administration, substantially limits their efficacy in
vivo as discussed (Chapter I) (70, 72, 74). The use of subcutaneous biodegradeable

polymeric implants for delivery of GTPs to circumvent low bioavailability following oral
exposure is explored here.
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Poly (epsilon-caprolactone) (PCL) is one of most common biodegradable materials
used in sub-dermal implant and importantly, its medical application has been approved
by the FDA (95, 96). In vivo, the hydrolytic degradation of PCL polymer molecules into a
smaller molecular weight polymer will lead to conversion of the implant to small
particles which will then be excreted. This process usually takes few months to years
based on the molecular weight of polymer. Polycaprolactone implants with 65,000
molecular weight are expected to take two or more years before they will degrade
completely and be excreted (97). The drug is released in concert with the physical erosion
of the implant, and more importantly, up taken into the blood and tissues as interstitial
fluid penetrates into the polymer (98). PCL is ideally suitable for long-term delivery
because of its slow degradation rate (96).
In our laboratory, we successfully prepared PCL implants containing GTPs, and
these implants can be administered subcutaneously (99).

This dosing method is

hypothesized to eliminate the poor bioavailability of GTPs following oral administration
found in previously published studies (72-74). I expect that in these studies the
pharmacological effects of GTPs will be greatly enhanced due to their expected increase
in plasma and tissue levels. The studies performed in this chapter were conducted to
characterize and optimize the delivery of GTPs from PCL implants.

Materials and Methods:
Chemicals
PCL, GTPs, F68, cyclodextrin, polyethylene glycol, molecular weight 8000 (PEG
8000), ECG, EC, EGC and GTP60 (a green tea extract preparation containing 60%
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catechins) were purchased from Sigma-Aldrich (St. Louis, MO, USA) and used for all in
vitro studies in this chapter unless mentioned otherwise. EGCG was purchased from LKT

laboratories, Inc. (St. Paul, MN, USA). Polyphenon E (a standard green tea extract
preparation containing approximately 90% catechins) was obtained from National Cancer
Institute and used for the in vivo study.

Preparation of GTP-PCL implants
Polymeric implants were prepared using the methodology described elsewhere (99).
Briefly, PCL and GTPs were dissolved in dichloromethane and ethanol respectively
before mixing, followed by removal of the solvents under reduced pressure (Savant
SpeedVac) overnight. The polymeric material was then filled in a disposable syringe
attached to silastic tubing (I.D. 3.2 mm), heated at 70°C and extruded. The implants were
removed from the silastic tubing mould and excised to desired length (0.5-3 cm length).
Polymer composition (PCLs with different molecular weights), supplements in the
implant (F68, cyclodextrin, PEG8000) and GTP load were variable based on the purpose
of studies.

Calibration curves of GTP60 in vitro
A calibration curve of GTP60 in phosphate-buffered-saline (PBS) with 10% bovine
serum was established by spiking the medium with a series of known concentrations of
GTP60 and measuring the O.D. values spectrophotometric ally at 540 nm after reaction
with a dying solution containing 0.1 % ferrous sulfate and 0.5% potassium sodium tartrate
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tetrahydrate (l00). The O.D. values were plotted against the concentration of GTPs. At
least three individual experiments were performed to generate a calibration curve.

The effect of polymer composition on G TP release in vitro
Implants of PCL of mol. wt. 65,000 (P65) and 15,000 (PI5) with different
compositions (0%, 10%, 30% or 50% P65) and 10% GTPs were prepared. Release of
GTPs from I cm implants was investigated by stirring the implants in 5 ml phosphatebuffered-saline (PBS) with 10% bovine serum, pH 7.4 at 37°C to mimic the in vivo
environment. The amount of catechins released was measured spectrometric ally as
mentioned above.

Overall degradation rate of G TP60 and poly E in vitro
The overall degradation rate of GTP60 in an in vitro environment was measured as
follows. GTP60, with a known concentration was dissolved in PBS containing 10%
serum and kept in amber colored vials at 37°C. An aliquot of this GTP60 solution was
sampled and measured spectrophotometric ally at different time points.
The overall degradation rate of poly E was obtained in the same method as above.

Degradation of GTPs determined by HPLC
Poly E solution in pure water, PBS or PBS with KOH (pH 12.4) was prepared and
analyzed by HPLC (Shimadzu Corp., Columbia, MD) coupled with a CI8 Sonoma
column, 25 cmx4.6 mm, particle size of 5 !-!m (ES industries, West Berlin" NJ) and
detected using a UV detector. Mobile Phase A was water with 0.05% trifluoroacetic acid
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(TFA), Phase B was acetonitrile with 0.05% TFA. The column was eluted with a linear
gradient from 12% to 21 % mobile Phase B in 25 min, and increased to 29% for another
10 min at a flow rate of 1 mllmin.

The effect of water soluble polymeric supplements (F68, Cyclodextrin,
PEG8000) in the PCL implants on GTP release in vitro
In order to determine whether incorporation of water-soluble polymeric
supplements into peL implants can modify GTP release into the medium, a total of four
groups were assigned. Implants containing 90% P65 and 10% GTP served as controls.
The other three groups employed implants containing 81 % P65, 10% GTP and 9% of
either F68, cyclodextrin or PEG8000. Release of GTPs from 1 cm implants in vitro was
measured as mentioned above.

The effects of drug load and implant surface area on GTP release in vitro
In order to determine the effects of the level of GTPs embedded in the implants as
well as variable levels of implant surface areas on GTP release into the medium, I tested
GTP release from 0.5-2 cm implants (corresponding to a surface areas of 2.30-1.075
2

mm /mg) with 5-20% of drug loads. A total of 9 groups were assigned containing 20%
GTPs of 0.5, 1.0 or 2.0 cm in length; 10 or 5 % GTPs of 1.0, 1.5 or 2.0 cm in length. All
test implants contained P65 and F68 with a ratio of 9: 1. Release of GTPs from implants
in vitro was measured spectrophotometrically as described previously.

G TP release in vivo
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In this study, I aimed to determine the rate of GTP release from subcutaneous
implants in ACI rats. The implants were composed of the active component, 20% poly E
(total of 40 mg), and the inert ingredients P65 and F68 with a ratio of 9: 1. A 2-cm
implant was surgically placed onto the back of the rat subcutaneously. At 1,2,3,5,8 and
19 wks, rats were euthanized and the implants were removed for further analysis. The
residual amounts of poly E in the implants were measured by dissolving the implant in a
mixture of dichloromethane and ethanol, extraction of the poly E in PBS, followed by
reaction with a dying solution and spectrophotometric detection described above and
back calculated based on the calibration curve generated by poly E in PBS without
serum. The amount of poly E released at selected time points was calculated by
subtracting the residual amounts of poly E from the initial amount.

GTP release from implant with PCL coating in vitro
In order to determine whether coating implants with a thin layer of blank PCL can
improve the sustained release profile of GTP from implants, the following experiment
was performed. GTP-PCL implants were prepared as described above. Then these
implants were dipped in 8% PCL solution in dichloromethane for 1 sec followed by air
dry and repeated sequentially six times. The release profile of these implants was tested
in vitro comparing with the release profile from implants without PCL coating.

Results:
Calibration curve of GTPs in PBS with 10% serum
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The calibration curve of O.D. versus GTP concentration (0 to 250 Ilg/ml) was found
to be linear at the given range with a correlation factor greater than 0.999 (Figure 2-1).

Effect of polymer composition on GTP release in vitro

Release of GTPs from the implants showed a continuous release of the GTPs as a
function of time (Fig. 2-2A). For example, the release of the GTPs from the implants
containing 50% P65 fits very well to a mathematic equation y

= 547.02x-O.8637, with a R2

equal to 0.9781, in which y is the daily GTP release and x is the time expressed in days
(Fig. 2-2B). Initially, the observed release of the GTPs is comparatively high during the
early time points, while the drug release is much slower at the later time points. A
theoretical cumulative release of GTPs was obtained by summing up the daily release
calculated by the equation above (Fig. 2-2C), however, only approximately 50% of the
initial amount of the drug infused in the implant was released during the 9 month study.
The plot of cumulative GTP release versus the square root of time was expressed as
Figure 2-2D. In this study, the PCL implants remained intact during the entire nine
months duration. A higher percentage of P65 was also found to increase the plasticity of
the implants which makes them less fragile. For these reasons, implants with a higher
percentage of P65 were used in all subsequent experiments.

Overall degradation rate of GTP60 and poly E in vitro

Degradation of GTPs varied as a function of time, faster initially and slower at later
time point (Fig. 2-3). The rate of degradation of GTP60 in PBS with 10% serum was
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found to be approximately 50% in 24 h. Under the same conditions, the degradation of
poly E was similar with degradation levels of 58% in a 24 h duration (Fig. 2-3).

Degradation of GTPs determined by HPLC
The degradation rate of GTPs was confirmed by HPLC (Fig. 2-4). The four
catechins clearly separated in the elution profile (Fig. 2-4A). The degradation of
catechins in PBS occurred within 1 h (Fig. 2-4B) and faster rates were observed in PBS
with potassium hydroperoxide (Fig. 2-4C). Results also showed EGCG and EGC were
more labile to degradation than EC and ECG (Fig. 2-4).

Effect of implant supplements (F68, Cyclodextrin, PEG8000) on GTP release
in vitro
In this study, I tested GTP release from implants with different supplement
compositions. The purpose of adding these water-soluble polymers was to facilitate the
preparation of the implants as well as obtain more sustained release of GTP. Our results
indicate that these supplements do not significantly alter the GTP release pattern from the
implants (Fig. 2-5) although the presence of these supplemented did facilitate extrusion
of the polymeric material into silastic tubing mould.

Effects of drug load and implant surface area on GTP release in vitro
The results showed that drug load is the determining factor of GTP release (Figure
2-6). One cm implants with 20% GTP load released more GTP than implants with 10%
and 5% drug load (Figure 2-6A). Similarly, two cm implants with 20% GTP load
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released more GTP than implants with 10% and 5% drug load (Figure 2-6B). The drug
release is proportional to the drug load, and the correlation is high (data not shown).
Comparison of implant sizes, 0.5, 1 and 2 cm containing 20% GTP load resulted in
higher release of GTPs initially from the smaller implants, but then the release declined
for the next several days (Fig. 2-7). Similar results were observed in 1, 1.5 and 2 cm
implants with lower drug loads of GTPs (Fig. 2-7). It should be noted that these data have
been normalized by implant weight, therefore, the shorter the implants are, the larger the
surface area of the implants. I found that the implants with a larger surface area initially
resulted in higher release. However, subsequently, the rate of GTP release was dictated
by the drug load.

GTP release from subcutaneous implants in vivo
Our results showed that in vivo release of GTPs from the implants follows a similar
pattern as found in vitro, initially a burst release followed by a decreased but continuous
release (Fig. 2-8). The total amount of poly E released following 1,2,3,5,8,19 weekes)
was approximately 18%,30%,38%,42%,47% and 60%, respectively.

GTP release from implants with blank peL coating
The result showed that the release of GTPs from implants with a PCL coating was
much less initially as compared with implants without the coating, dropping from
approximately 4.8% to l.9% on the 1st day and 2.5% to l.2% on the 2nd day. In fact, the
GTP release from these two groups was almost identical after 9 days, with levels of 0.6%
and 0.5% respectively, which indicates that the implants coated with a blank layer of
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PCL released GTP at more constant rate than those implants without the PCL coating
(Figure 2-9).

Discussion:
The studies in this chapter were conducted to characterize and optimize the release
of GTPs from polymeric implants both in vitro and in vivo. In vitro studies were
conducted using a mock environment to mimic the in vivo situation in order to establish a
baseline for further in vivo evaluation. In vitro release of the GTPs from the GTP60
implant, as measured spectrophotometric ally, showed a continuous decline with time.
Interestingly the release of GTPs from implants can be expressed as y = AxB, in which y
is the daily GTP release, x is the time expressed in days and A and B are constants (Fig.
2-2B). This mathematical expression of GTP release describes firstly that the release of
GTPs from the implant is comparatively high during the early time points, while the drug
release is much slower at the later time points. Secondly, it suggests that release is a
simple diffusion mediated, in which the readiness of GTP molecules released from implants is
inversely proportional to the square of the distance between the molecules and the implant
surface. Thus, a plot between the cumulative GTP release versus square root of time should
result in a straight line, which is indeed the case as illustrated in Fig. 2-2D. The deviation
of the initial time points from the straight line are presumably due to the elapsed time
needed for water to penetrate into the implants thoroughly to flush out the GTPs.
Another interesting finding is that the cumulative release of the GTPs measured
spectrophotometric ally was approximately 50% of drug load (Fig. 2-2C) suggesting
degradation of the GTPs may be occurring once they are released into an aqueous
environment. The loss of GTPs can be attributed to many environmental factors,
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including light and aIr exposure, which make the accurate determination of the
degradation rate of these compounds problematic. A preliminary study was therefore
conducted to determine the rate of degradation of GTPs. The result indicates that
approximately 50% of GTPs are degraded within 24 hrs (Fig. 2-3), which explains our
previous result that approximately 50% of the total GTPs were released from the implant
following a 9 month exposure to an aqueous environment at biological pH. It also
indicates that the daily release of GTPs from the implant is actually double the value
initially found in the previous experiment. The degradation of GTPs is confirmed by
HPLC, in which EGCG is more labile to degrade (Fig. 2-4).
Other factors that may affect GTP release, including polymer composition,
supplements (F68, cyclodextrin, PEG8000), drug load and surface area of the implants
have been studied here, and indicate only drug load plays a key role. Polymer
composition and use of supplements (F68, cyclodextrin, PEG8000) do not significantly
affect the drug release. The surface area of the implants exhibited some effect on GTP
release only during the first several days. At later time points, the drug load appeared to
dictate the release. Although F68 does not have significant effect on GTP release, it
facilitates the preparation of the implants because it is a surfactant and aids the molding
process by decreasing the viscosity of the polymers. In the animal study, 10% F68 was
included in the formulations for these reasons.
The release of GTP in vivo follows the same pattern as in vitro. Although some
differences of GTP60 used for in vitro studies and poly E used for the in vivo study were
observed, it is still reasonable to compare the in vitro and in vivo release. Essentially it
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can be concluded that the in vitro studies correlated well with the in vivo situation and are
thus reasonable predictors of the rate of drug release in vivo.
In these studies, one drawback of the GTP polymeric implants is that the release of
the GTPs is comparatively high during the early time points, while the drug release
diminishes significantly at the later time points. The variation in drug concentration could
possibly result in either toxicity or lack of efficacy in future animal studies. In order to
improve the release profile of the implants, a PCL coating was used to limit the initial
burst release. Therefore, it was hypothesized that the initial burst rate of GTP release be
lower resulting in an overall more uniform release rate. In the last experiment in this
chapter, I demonstrated that release profile of GTPs can be modified by coating GTPPCL implants with blank PCL and that indeed resulted in a more uniform rate of GTP
release (Fig. 2-9).
In conclusion, my studies showed that GTPs are released from these PCL implants
in a continuous fashion and the in vitro and in vivo release rates follow a similar fashion
and the release profile of GTPs can be optimized by coating GTP-PCL implants with
blank PCL.
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GTPs: green tea polyphenols; PCL: Poly

CHAPTER III: EFFECT OF GREEN TEA CATECHINS AND HYDROL YSABLE
TANNINS ON BENZO[a]PYRENE-INDUCED DNA ADDUCTS AND
STRUCTURE ACTIVITY RELATIONSHIP

Introduction:

Benzo[a]pyrene (BP) is a polycyclic aromatic hydrocarbon (101), which is present
ubiquitously in tobacco smoke, automobile exhaust emissions and grilled foods (14, 15).
It is one of the most potent environmental carcinogens. Numerous studies have

demonstrated the association of BP exposure and induction of carcinogensis in many
organs including lung, skin, mammary gland and others (16-18).
Enzymatic activation of BP by certain types of cytochrome P450s (CYPs) found in
the subcellular microsomal fraction, especially CYPIAl, are needed to produce the
ultimate carcinogen anti-benzo[a]pyrene-7,8-diol-9,1O-epoxide (anti-BPDE) (19). antiBPDE exerts its carcinogenic activity by alkylating nucleosides on DNA molecules at the
bay region of anti-BPDE. The reaction primarily happens with the purine bases,
deoxyguanosine and deoxyadenosine in DNA (20). As a result, bulky stable and
depurinating DNA adducts are formed (21, 22). Insufficient removal of these DNA
adducts prior to replication creates hot spots in the gene and can result in deactivation of
tumor suppressor genes or activation of oncogenes leading to tumor initiation (23).
Green tea is one of the most popular drinks in the world with some beneficial
effects on cardiovascular (42, 43) and neurodegenerative diseases (44). Green tea is now
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drawing increasing attention because of its possible application in cancer prevention
(102, 103). Green tea preparations were found to decrease tumor incidence and tumor

multiplicity in chemically-induced tumor models, including BP and other PAHs (41, 5054, 104). Interestingly, green tea preparations were effective when administered to mice

either during or after carcinogen exposure (50, 51), suggesting their chemopreventive
effects in different phases of carcinogenesis.
The catechins in green tea are thought to be the bioactive components, including
epicatechin

(EC),

epigallocatechin

(EGC),

epicatechin

gallate

(ECG)

and

epigallocatechin gallate (EGCG), which bear close structural similarities (Fig. 3-IA).
EGCG is the predominant catechin (105). Many mechanisms of action of green tea
catechins have been proposed based on studies in vitro. Green tea catechins were found
to induce apoptosis and inhibit the proliferation of a variety of cancer cell types (45-49).
Green tea catechins can generate reactive oxygen species (ROS), including hydrogen
peroxides which are responsible for death of cancer cells (59, 60). However, these
mechanisms of action are more relevant to the chemotherapeutic effects of green tea
catechins, rather than their chemopreventive effects (57).
As noted above, DNA adduct formation is the initial key step in the BP-induced
carcinogenisis process. Since green tea manifests its chemopreventive effects in almost
all the animal studies conducted, I hypothesize that green tea should be able to inhibit the
DNA adduct formation induced by BP. This notion has been supported by a limited
number of studies, in which green tea components decreased BP-induced DNA damage
in the Chang liver cell line evaluated by the comet assay (106) and EGCG inhibited the
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formation of eH]-BP-derived DNA adducts in a cell-free system (107). However, the
mechanism behind these effects is not known.
Back in the early 80s, Conney and co-workers showed that the plant phenolic
ellagic acid was highly potent in inhibiting the mutagenesis by anti-BPDE (108).
Subsequently this group demonstrated that this inhibition occurred due to covalent
interaction of ellagic acid with anti-BPDE (109). This finding was later supported by
inhibition of anti-BPDE-induced DNA adducts (110). Green tea extract which contains
several catechins with cis-diol groups, like in ellagic acid, was reported to decrease antiBPDE-induced DNA strand breaks (111), presumably by the same mechanistic action of
ellagic acid reported by Sayer et al. (109). Additionally, Bors and Michel (112) and RiceEvans et al. (113) demonstrated that the cis-diol groups in green tea catechins could
scavenge free radicals such as hydroxyl radicals, azide radicals and superoxide anions,
thus correlate with their antioxidant activities.
I hypothesized that green tea catechins will inhibit BP-induced DNA adduct
formation by direct quenching of anti-BPDE produced in the metabolism of BP, and that
the potency of different catechins will vary with the number of their cis-diol groups. This
structure activity relationship (SAR) study will help to further identify the mechanism of
action of green tea catechins. It might also be beneficial for drug modification and drug
development based on catechins or compounds bearing similar groups.
This hypothesis cannot be readily tested in a whole cell system because many
factors such as the lipid solubility of the catechins, etc. could bias the interpretation. I
therefore used a microsomal system to assess the capacity of various catechins in green
tea to inhibit DNA adduct formation and determine SAR. Two hydrolysable tannins,
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pentagalloylglucose (5GG) and tannic acid (penta-m-digalloyl-glucose), which have
more number of cis-diol in their structures (Fig. 3-1B) than the catechins were also
included to further test the SAR.

Materials and Methods:
Caution: Both BP and anti-BPDE are mutagenic and carcinogenic. Protective
clothing should be worn, and appropriate safety procedures should be followed when
working with these compounds.

Chemicals. EC, EGC, ECG, tannic acid, glucose-6-phosphate, glucose-6-phosphate
dehydrogenase from baker's yeast (G6PDH), NADP+, BP and salmon testis (st)-DNA
were purchased from Sigma-Aldrich (St. Louis, MO, USA).

EGCG was from LKT

laboratories, Inc. (St. Paul, MN, USA). 5GG was obtained from Sinova, Inc. (Bethesda,
MD, USA). Anti-BPDE was kindly provided by Dr. Subodh Kumar, State University of
New York College at Buffalo. Chemicals used in 32P-postlabeling DNA adduct analysis
were the same as described previously (114).

Microsomal BP-induced DNA Adducts. Green tea catechins and hydrolysable
tannins were dissolved in Me2S0 and prepared freshly. St-DNA (300 !Ag/ml) was preincubated with 50 mM Tris-HCI (pH 7.5), 1 mM MgCh, 2.5 mM glucose-6-phosphate, 1
Ulml G6PDH, 0.5 mM NADP+, ~-naphthflavone-induced microsomal proteins (1 mg/ml)
in Iml for 10 min, in the presence of vehicle alone or green tea catechins or hydrolysable
tannins (1-200 !AM). BP dissolved in Me2S0 was added at a final concentration of 1 !AM,
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and incubation was continued for another 30 min at 37°C. The reaction was terminated by
addition of EDTA and centrifugation (7500 rpm; 10 min). DNA was isolated from the
supernatant by removal of RNA and proteins by digestions with RNases A and Tl and
proteinase K, and a series of extractions with phenol, phenol:Sevag (chloroform:isoamyl
alcohol, 24: 1) and Sevag, followed by precipitation of the DNA with ethanol (J 14). The
DNA concentration was estimated spectrophotometrically.

Reaction of st-DNA with anti-BPDE. St-DNA (200 !Ag/ml) was pre-incubated
with 50 mM Tris-HCI (pH 7.S) in a total of 0.2 ml solution for 10 min, in the presence of
vehicle or green tea catechins or hydrolysable tannins. Then, anti-BPDE was added at a
final concentration of O.S !AM and incubated at 37°C for another 30 min. The reaction was
terminated by precipitating DNA with ethanol, and the DNA concentration was measured
spectrophotometricall y.

Analysis of DNA Adducts. DNA adducts were analyzed by 32P-postlabeling as
described (J 14). Briefly, 10 !Ag DNA was digested with micrococcal nuclease and spleen
phosphodiesterase (MN/SPD). Before further treatment with nuclease PI to enrich DNA
adducts, an aliquot was used for evaluation of normal nucleotide levels. DNA adducts
and normal nucleotides were labeled with [y_32 p ]ATP and T4 polynucleotide kinase.
Labeled DNA adducts were separated by multi-directional polyethyleneimine (PEI)cellulose TLC in the following solvents: D 1 = 1.0 M sodium phosphate, pH, 6.0; D3 = 4
M lithium formatel7 M urea, pH 3.S; D4
(1.1:1), DS

=4

M ammonium hydroxide/isopropanol

= 1.7 M sodium phosphate, pH 6.0. Normal nucleotides were resolved in 180
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mM sodium phosphate, pH 6.0 by one-directional PEl-cellulose TLC. DNA adducts and

normal nucleotides were detected and quantified by Packard InstantImager.

ESI/MS and ESI/MS/MS Study. Anti-BPDE and test compounds (green tea
catechins and hydrolyzable tannins) were incubated at 37°C at equimolar concentration
(500 [,tM) in H2 0 and acetonitrile (9: 1) for 40 min. Reaction products were diluted with
50% acetonitrile/O.l % formic acid and analyzed by ESIIMS in positive ion mode and
mass resolution of 10,000 with a Q-TOF API-US mass spectrometer from Waters
(Milford, MA). Samples were infused with a syringe pump at 1 [,tUmin. Data acquisition
lasted for at least 1 min after the signal was stabilized and the spectra were summed,
smoothed, and stored. For MSIMS analysis, the collision energy was adjusted to a level
such that the intensities of the precursor ions were decreased by 80 to 90%.

LC/MS and LC/MS/MS Study. Anti-BPDE and EGCG were incubated at 37°C at
equimolar concentration (100 [,tM) in H2 0 and acetonitrile (9: 1) for 40 min. DNA adduct
separation was performed by Accela LC from Thermo Scientific (San Jose, CA) with a
Hypersil GOLD 50 x 2.1 mm C 18 column. A 15 min gradient with 5% acetonitrile/O.l %
formic acid (Solvent A) and 95% acetonitrile/O.l % formic acid (Solvent B) at 0.1
mUmin was used. The gradient started from 5% Solvent B that increased linearly to 50%
in 12 min and then increased linearly to 75% in 3 min. Elute from LC was coupled to a
LTQ Orbitrap XL mass spectrometer from Thermo Scientific (San Jose, CA) via an ESI
source. MS and MSIMS spectra were acquired in positive ion mode at 30,000 mass
resolution.
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Statistical Analysis. Results were reported as means ± SEM. The Students t-test
was used for the determination of statistical significance between two individual groups.
A p-value less than 0.05 with a 95% confidence interval was considered to give the level
of significance.

Results:
Before testing the efficacy of these various phenolic compounds, I first determined
the lowest concentration of BP in a microsomal reaction that would produce measurable
levels of DNA adducts detected by the highly sensitive 32P-postlabeling assay. Incubation
of st-DNA with

~-naphthaflavone-induced

rat liver microsomes, which exhibit increased

expression of CYPIAI and CYPIB1, in the presence of varying concentrations of BP
(0.5 to 10 flM) and co-factors resulted in the formation of two major DNA adducts (Fig.
3-2). These DNA adducts have previously been characterized as the products of the
interaction of anti-BPDE (DNA adduct 1) and 9-0H-BP-4,5-epoxide (9-0H-BPE) (DNA
adduct 2) with dG (20, 115).
Total DNA adduct levels increased with increasing concentration of BP (l5±6 to
467±49 DNA adducts/l07 nucleotides). The relative levels of DNA adducts 1 and 2
varied with BP concentrations. At the highest concentration of BP (10 flM), 9-0H-BPEdG levels were slightly greater than anti-BPDE-dG levels (9-0H-BPE-dGlanti-BPDE-dG
=1.6). However, the ratio of the two DNA adducts increased with decreasing BP
concentrations (9-0H-BPE-dGlanti-BPDE-dG= 4.5 at 0.5 flM BP), indicating that
metabolism of BP to DNA-reactive metabolites is dose-dependent and reflective of the
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relative amount of substrate. All subsequent reactions in the presence of the phenolic
compounds were performed using relatively low concentration of BP (1

~M).

Effect of Green Tea Catechins on Microsomal BP-DNA Adducts
Incubation of st-DNA with BP (l
concentrations (l - 200

~M)

~M)

in the absence or presence of varying

of EC, EGC, ECG and EGCG produced qualitatively the

same DNA adduct profile (data not shown). Quantitatively, however, BP-DNA adduct
levels varied with the type of catechin (Fig. 3-3A). Compared with BP alone (25.2 ± 1.8
DNA adducts/l07 nucleotides; n = 4), each catechin tested (100 ~M) resulted in
significant inhibition of BP-induced DNA adducts, with EGCG (75%) > ECG (66%) >
EGC (39%) > EC (27%). Further, the DNA adduct inhibition observed with each
compound was dose dependent (Fig. 3-3A).
When the percent DNA adduct inhibition was plotted against the various catechin
concentrations, a clear dose-response was observed in the form of a sigmoid curve (Fig.
3-3B). EGCG and ECG were the most potent components of green tea catechins, with
half maximal inhibitory concentration (ICso ) values of 16 and 24

~M,

respectively. The

other two compounds, EGC and EC were least effective showing IC so values of 146 and
462

~M,

respectively.

To determine the structure-activity relationship, VIC so was plotted against the
number of adjacent OR groups in their molecular structure. A clear relationship was
evident (Fig. 3-3C), suggesting that the activity may reside in the cis-diol groups.

Effect of Hydrolysable Tannins on Microsomal BP-DNA Adducts
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In order to further prove that the activity lies in the cis-diol groups, I investigated
the effect of SGG and tannic acid, which are hydrolysable tannins. The rationale for the
use of these compounds is that they contain a higher number of adjacent OH groups in
their molecular structure, as compared to the green tea catechins, IS for SGG and 2S for
tannic acid (see Fig. 3-1B). Therefore, it is reasonable to expect that these compounds
may be more efficacious than green tea catechins against BP-DNA adduction. As shown
in Figures 3-4A and 3-4B, both of these compounds showed effective inhibition of
microsomal BP-DNA adducts, and the inhibition was dose-dependent. Both SGG and
tannic acid elicited almost complete DNA adduct inhibition, with tannic acid being much
more potent than SGG (ICso <4 and 26 !!M, respectively). It is also interesting to note that
the dose-response sigmoid curves were parallel to each other presumably due to their
extreme structural similarities.

Effect of Green Tea Catechins and Hydrolysable Tannins on anti-BPDE-DNA
Adducts
To determine the mechanism by which the test cis-diol-containing green tea
catechins and the hydrolyzable tannins inhibit microsomal BP-DNA adduction, these
compounds were studied in a non-enzymatic reaction, i.e., anti-BPDE (O.S !!M), the
ultimate carcinogenic metabolite of BP was incubated with st-DNA (200 !!g/ml) in the
presence of vehicle alone or EGCG, ECG, SGG and tannic acid (200 !!M each), followed
by analysis of the DNA adduct levels by 32P-postlabeling. As shown in Figure 3-S, all
compounds showed effective inhibition of anti-BPDE-dG. However, the degree of
inhibition with the test compounds varied: tannic acid (98% inhibition) > SGG (68%) >
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EGCG (64%) > ECG (39%). These data further support our earlier conclusion that the
higher the number of adjacent OH groups, the greater the DNA adduct inhibition. These
data also suggest that inhibition of microsomal BP-DNA adducts by the catechins and
test hydrolyzable tannins is at least, in part, due to their direct interaction with the
electrophilic metabolites of BP.

Detection of anti-BPDE-catechin Complex by ESI/MS/MS
This analysis was performed to detect the reaction products in the reaction mixtures
of anti-BPDE and test compounds (green tea catechins and hydrolysable tannins). All
showed clear peaks with the expected mass for the complexes formed. For example, a
peak with a mlz ratio of 761 corresponding to anti-BPDE-EGCG complex was found in
the anti-BPDE-EGCG reaction mixture; MSIMS spectrum of the complex further
suggested a direct covalent interaction of anti-BPDE and EGCG (data not shown).

Investigation of Fragmentation Pattern of anti-BPDE-EGCG Complex by
LC/MS/MS
LCIMSIMS analysis was performed to further rule out the possibility of noncovalent interaction between EGCG and anti-BPDE, and also to investigate the
fragmentation pattern of anti-BPDE-EGCG complex. Several peaks with mlz ratio of 761
in the spectrum, which corresponding to anti-BPDE-EGCG complex, were found. Their
retention times were 5.70,8.51,9.56,10.17,10.51,10.59,11.30,11.47,11.66 and 11.96
min (Fig. 3-6A). The MS/MS studies of each peak were performed and two major
fragmentation patterns were found in the spectrum. The peaks with retention times of
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8.51, 9.56, 10.17, 11.30, 11.47, 11.66 and 11.96 all generated a fragmentation pattern in
which a fragment with rn/z ratio of 591 and another fragment with rn/z ratio of 303 exist
suggesting anti-BPDE attacks the hydroxyl groups on the B ring of EGCG molecules
(Fig. 3-6B). The peaks with retention times of 10.51 or 10.59 min generated a different
fragmentation pattern in which a fragment with rn/z ratio of 455 and another fragment
with rn/z ratio of 307 exist suggesting anti-BPDE attacks the hydroxyl groups on the D
ring of EGCG molecules (Fig. 3-6C). Based on the data gathered, two possible antiBPDE-EGCG complexes are proposed (Figs. 3-6B, 3-6C).

Discussion:
In this study, I used a range of EGCG (116) and other catechins and hydrolysable
tannins to show dose-dependent inhibition of microsome-mediated BP-induced DNA
adducts. Some of the catechins (e.g., EGCG) and hydrolysable tannins (tannic acid)
showed nearly 50% inhibition of the adduct formation at as low as 16 and 4 !J,M
concentrations, respectively. The higher concentrations of test agents were necessary to
combat the somewhat high concentration of BP used in order to be able to reliably
quantify the resultant DNA adducts. The plasma concentration of EGCG in rodents and
in human volunteers is reported to vary with the dosing of green tea extracts. For
example, when high pharmacological doses of EGCG was given to mice (2000 mg/kg)
(117) or polyphenon E (containing 1200 mg EGCG) given to human volunteers (118)

orally, peak plasma concentrations found were approximately 9 !J,M and 7.5 !J,M in mice
and humans, respectively. Typical achievable plasma EGCG concentration of sub micro
molar has also been reported after two or three cups of tea consumption in humans (74).
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A study by Bors and Michel found the reaction rates of green tea catechins and
gallate esters against hydroxyl radicals, azide radicals or superoxide anions correlate
with catechol and pyrogallol groups in their molecular structures (112), which may
explain the antioxidant properties of these compounds. In this study, I demonstrate a clear
correlation of adjacent aromatic hydroxyl groups in the molecular structure of green tea
catechins and hydrolysable tannins with the inhibitory effects of these compounds on
DNA adduct formation induced by BP. Interestingly, it is nearly an exponential
relationship between the number of adjacent aromatic hydroxyl groups and ICso of these
catechins. There are at least two possible mechanisms through which these compounds
can decrease BP-DNA adduct formation, either through interacting with reactive
intermediates or interfering with microsomal enzyme activities (eg. CYPIAl). Green tea
catechins have inhibitory effects on CYPIA1 activity with the following descending
order: ECG::::; EGCG > EC ::::; EGC (119). In our study, all the catechins interacted with
anti-BPDE directly, indicating an exponential relationship with EGCG and ECG being

much more potent than the other two catechins studied.
The higher efficacy of the two hydrolysable tannins is due to a greater number of
functional hydroxyl groups in their molecular structures. With regards to the potency, the
more functional hydroxyl groups in green tea catechins correspond to lower IC so values.
This conclusion also holds true in hydrolysable tannins with tannic acid being more
potent than 5GG. However, the problem arises when we compare the IC so of EGCG and
5GG, which are about 16 f!M and 26 f!M, respectively, while apparently 5GG has more
functional hydroxyl groups than EGCG. This is probably because the potency of the
compounds could also be affected by the basic structures. The molecular structure of
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green tea catechins and hydrolysable tannins are quite different although some
similarities exist, so the comparison of these two compounds may not be appropriate.
In this study, the covalent reaction of anti-BPDE and EGCG was demonstrated
through ESIIMSIMS and LCIMSIMS. The hydroxyl groups on either B ring or D ring of
EGCG molecules (Figs. 3-6B, 3-6C), but not both, were found to react with anti-BPDE
thus sequestering anti-BPDE. This finding suggests that EGCG share the same
mechanism of action with ellagic acid which also interacts directly with anti-BPDE and
lead to sequestration of anti-BPDE (109).
Our MS studies on anti-BPDE-EGCG complex did not provide information on the
exact position of the hydroxyl groups which react with anti-BPDE. The hydroxyl group
on EGCG could be the 3' ,4' or 5' on the B ring or the 3",4" or 5" on the Dring (see Fig
3-1A). NMR studies may be necessary to address this question. It is interesting to note
that there are several peaks corresponding to rnJz ratio of 761 in LC-MS spectrum in antiBPDE-EGCG reaction (Fig. 3-6A). This is probably because anti-BPDE has two optical
enantiomers and also anti-BPDE can attack different positions on B ring or D ring of
EGCG molecules, which produce different complexes with different retention times as
shown in our results.
The significance of the present study is to demonstrate a new mechanism of action
of test catechins. Structure activity relationship of green tea catechins and hydrolysable
tannins illustrated in this study may help us discover other chemopreventive reagents. It
will also be useful in drug modification and development based on these compounds or
compounds with similar molecular structures.
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In conclusion, our data demonstrate that green tea catechins and the hydrolysable
tannins are highly effective in inhibiting BP-DNA adduct formation at least, in part, due
to direct interaction of adjacent hydroxyl groups in their structures, and that the activity is
higher with an increasing number of functional hydroxyl groups.
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Fig. 3-1. Chemical structures of catechins and two hydrolysable tannins. A: (-)epicatechin (EC), (-)-epigallocatechin (EGC), (-)-epicatechin gallate (ECG), (-)epigallocatechin gallate (EGCG). B: pentagalloylglucose (R=H) and tannic acid
(R=galloyl group as shown on the right).
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Fig. 3-2. Representative autoradiographs of 32p-postlabeling analysis of microsomemediated BP induced DNA adducts. (a) vehicle (2% DMSO) and (b) 1 !AM BP. OR,
origin. DNA adducts were resolved by multi-directional polyethyleneimine (PEI)cellulose TLC using the following solvents: D 1 = 1.0 M sodium phosphate, pH, 6.0; D3
4 M lithium formate17 M urea, pH 3.5; D4
(l.1:1), D5
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M sodium phosphate, pH 6.0. DNA adducts were detected by Packard

Instan tImager.
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CHAPTER IV: SUSTAINED SYSTEMIC DELIVERY OF GREEN TEA
POLYPHENOLS BY POLYMERIC IMPLANTS SIGNIFICANTLY DIMINISHES
BENZO[a]PYRENE-INDUCED DNA ADDUCTS

Introduction:

Lung cancer is the second most common cancer type in men and women, only less
than prostate cancer in men and breast cancer in women. However, lung cancer accounts
for the highest cancer-related deaths, 31 % in men and 26% in women (120). Effective
prevention and treatment strategies are therefore urgently needed.
Green tea is one of the most popular drinks in the world. It is now drawing more
attention because of its possible chemoprotective effects. Green tea polyphenols (GTPs),
including epicatechin (EC), epigallocatechin (EGC), epicatechin gallate (ECG) and
epigallocatechin gallate (EGCG) are believed to be the active components. These
bioactive components of green tea along with green tea preparations have been shown to
exert their chemopreventive effects in vitro (58, 103).
In vivo, green tea consumption decreased lung tumor incidence and tumor

multiplicity in chemically-induced lung tumor models, including polycyclic aromatic
hydrocarbon (101)- and nitrosamine-induced tumor models (41, 50-54). However,
reviews on epidemiological and clinical studies indicated only a marginal beneficial
association between green tea consumption and lung cancer risk (63, 64). Similarly,

56

green tea did not show definite effects on other cancer types, including gastric, colorectal
and breast cancer (65-69). One major reason for the lack of consistent protection with
GTPs is their lack of bioavailability following oral intake, which ultimately affects their
blood levels (70, 74). Studies have shown that only about 0.1 %-3% of EGCG and ECG
were bioavailable following oral administration (72, 73, 75). In an effort to circumvent
the lack of bioavailability associated with oral delivery of GTPs as well as many other
chemopreventive agents, this laboratory has developed a novel delivery approach. In this
approach, test agents are embedded in cylindrical polymeric implants, which upon
subcutaneously grafting provide continuous systemic delivery of the test agents for an
extended duration (99).
Benzo[a]pyrene (BP) represents a model PAH to study lung cancer. It is also one of

the most potent and environmental carcinogens present ubiquitously in tobacco smoke,
automobile exhaust emissions, grilled foods and other sources (14, 15). In this study,
polyphenon E (poly E), a standardized green tea extract, was administered by polymeric
implants or via drinking water to female Sprague-Dawley (SID) rats. Animals were
challenged with continuous low-dose BP via subcutaneous polymeric implants (121).
Effects of poly E administered by the two routes were compared to determine its efficacy
against DNA adducts induced by continuous exposure to BP. Potential mechanisms of
action of poly E were also investigated by analysis of mRNA and enzyme activity of
several phase I, phase II and nucleotide excision repair enzymes.

Materials and Methods:
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Chemicals. Poly E was a generous gift from Pharma Foods International Co., LTD
(Kyoto, Japan). EC, EGC and ECG were purchased from Sigma-Aldrich (St. Louis, MO).
EGCG was from LKT laboratories, Inc. (St. Paul, MN). Chemicals used in

32 p _

postlabeling DNA adduct analysis were the same as described previously (114). All other
chemical reagents were purchased from Sigma-Aldrich (St. Louis, MO). Anti-CYPIAI
rabbit polyclonal IgG, GSTMI rabbit polyclonal IgG, UGTIA mouse monoclonal IgG,
goat anti-rabbit secondary antibody were purchased from Santa Cruz Biotech (Santa
Cruz, CA). Anti-B-actin mouse monoclonal antibody was from Sigma-Aldrich (St. Louis,
MO). Anti-CYPIBI rabbit polyclonal IgG was obtained from BD Biosciences (San Jose,
CA). Horse anti-mouse secondary antibody was from Cell Signaling Technology
(Danvers, MA). Other reagents used were from the following sources: Trizol (Invitrogen
Corporation, Carlsbad, CA), high capacity reverse transcription kit and Power SYBR
Green PCR master mix (Applied Biosystems, Foster City, CA), Pierce® BCA Protein
Assay Kit (Thermo Fisher Scientific, Rockford, IL.), and ECL plus detection kit
(Amersham Biosciences, Piscataway, NJ).

Polymeric implants. Polymeric implants of poly E and BP were prepared by
embedding them in a polymeric matrix comprised of a water-insoluble polymer,
polycaprolactone (P65) (mol. wt. 65,000) using the methodology described elsewhere
(99). Briefly, the polymer P65 was dissolved in dichloromethane and added to a solution
of poly E in ethanol. For BP implants, the polymer and BP were both dissolved in
dichloromethane. Following evaporation of the solvent(s) at 70°C with agitation with a
glass rod, the polymer matrix was completely freed of the solvents under reduced
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pressure overnight. The polymeric material was then filled in a disposable synnge
attached to a silastic tubing (LD. 3.2 mm), heated at 70°C and extruded. The implants
were removed from the silastic tubing mould and excised to desired length.

In vitro release of poly E from the implants. Release of poly E was investigated

by stirring the implants (2 cm, 200 mg implant containing 40 mg poly E) in phosphatebuffered-saline (PBS) supplemented with 10% bovine serum, pH 7.4 at 3rC to simulate
the

in vivo environment.

The

amount of catechins released was

measured

spectrophotometrically at 540 nm after reaction with a dyeing solution containing 0.1 %
ferrous sulfate and 0.5% potassium sodium tartrate tetrahydrate (l00).

Animal handling. Six week-old female SID rats were purchased from HarlandSprague-Dawley (Indianapolis, IN). After acclimation for 3 d, animals were randomized
into six groups and provided 4% Teklad diet. One week later, animals were treated with
BP, poly E or sham treatments as follows:
Group 1, No treatment
Group 2, Sham implants
Group 3, BP implant (2 cm, 200 mg implant containing 20 mg BP)
Group 4, BP implant + poly E implants (two, 2-cm 200 mg implant containing a 40
mg poly E/implant)
Group 5, BP implant + poly E in drinking water (0.8% w/v)
Group 6, Poly E implants

59

Sham, BP and poly E implants were grafted subcutaneously under anesthesia as
described previously (122). Poly E was given in drinking water two days prior to BP
implantation. Poly E solution was prepared in deionized water every other day by heating
the solution at 90°C with stirring for 3 min. This solution was cooled and stored at 4°C
until use. Animals from Groups 1-6 (n

= 5)

were euthanized one week following BP

implantation (Group 6 had only 2 animals) . Additional animals in Groups 1-4 (n

= 5)

were euthanized 4 weeks following BP implantation. Lung and liver tissues were
collected and stored at -80°C until use. Blood was collected by cardiac puncture and
plasma was collected by mixing with heparin and centrifugation. One ml plasma sample
was mixed with 20 III of 0.4 M NaH 2 P04 containing 20% ascorbic acid and 0.1 % EDT A
(pH 3.6) and stored at -80°C until analysis as described (76). All animal experiments
were performed after seeking approval from the Institutional Animal Care and Use
Committee (IACUC).

Stability of GTPs in polymeric implants. GTPs were released from the implants
by dissolving them in 10 ml of dichloromethane and ethanol (1: 1), followed by extraction
with water and centrifugation. The supernatant containing poly E catechins was filtered
by passing through a 0.22 Ilm centrifugal filter (Millipore Corp., Billerica, MA). Finally,
the eluate was analyzed by HPLC (Shimadzu Corp., Columbia, MD) coupled with a C18
Sonoma column, 25 cmx4.6 mm, particle size of 5 Ilm (ES industries, West Berlin, NJ)
and detected by a diode array detector. Mobile Phase A was water containing 0.05%
trifluoroacetic acid (TFA), and Phase B was acetonitrile Containing 0.05% TFA. The
column was eluted with a linear gradient from 12% to 21 % mobile Phase B in 25 min,
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and increased to 29% for another 10 min at a flow rate of 1 ml/min. Unused implants and
implants recovered from the animals were stored under argon until analysis of poly E
catechin levels.

Measurement of poly E doses. The total doses of poly E administered by the
implants or via drinking water were calculated as follows:
The dose of poly E in the implant group

=initial amount of poly E per two implants

- residual amounts in two implants
The initial and residual amounts of poly E in the implants were measured by
dissolving implants in a dichloromethane:ethanol mixture and extraction of the mixture
with water as described above, followed by derivatization of the poly E catechins and
spectrophotometric measurements (100).
The total dose of poly E in the drinking water group

= the concentration of poly E

(0.8%) x the amount of water consumed daily per animal x duration of the study in days.

Isolation of DNA, RNA, and microsomes and cytosolic fractions
DNA isolation. DNA from lung tissue was isolated by a solvent extraction
procedure involving isolation of crude nuclei, removal of RNA and protein by sequential
treatments with RNases and proteinase K, respectively, extractions with phenol,
phenol:Sevag and Sevag and finally precipitation of DNA with ethanol (114). DNA
concentration was estimated spectrophotometric ally.
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RNA isolation. RNA from lung tissue was isolated using Trizol reagent following
the Vendor's protocol. The quantity and purity of RNA was tested by Nanodrop. The
integrity of RNA was tested by agrose gel.
Microsome and cytosolic fractions. Lung tissue (300 mg) was homogenized in 0.25
M sucrose buffer with 0.1 mM EDTA (pH 7.4), centrifuged at 11,000xg for 20 min,
followed by centrifugation of the supernatant at 100,000xg for 60 min. The supernatant
was collected as cytosolic fraction. The pellet containing micro somes was resuspended in
sucrose buffer. Protein concentrations of microsomal and cytosolic fractions were
determined by using a BCA protein assay kit.

Analysis of DNA adducts. DNA adducts were analyzed by 32P-postlabeling as
described (114). Briefly, 10 Ilg DNA was digested with a mixture of micrococcal
nuclease and spleen phosphodiesterase. Before further treatment with nuclease PI to
enrich adducts, an aliquot was used for evaluation of normal nucleotide levels. Adducts
and normal nucleotides were labeled in parallel with [i 32 p]ATP and T4 polynucleotide
kinase. Labeled adducts were separated by multi-directional polyethyleneirnine (PEI)cellulose TLC in the following solvents: Dl = 1.0 M sodium phosphate, pH, 6.0; D3 = 4
M lithium formatel7 M urea, pH 3.5; D4
(1.1: 1), D5

= 1.7 M sodium phosphate,

=4

M ammonium hydroxide/isopropanol

pH 6.0; D2 development was omitted. Normal

nucleotides were resolved in 0.18 M sodium phosphate, pH 6.0 by one-directional PEIcellulose TLC. Adducts and normal nucleotides were detected and quantified by Packard
InstantImager. The adduct levels were calculated as relative adduct labeling (RAL), i.e.,
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= cpm of adduct/cpm

RAL

of normal nucleotides x lIdilution factor. The levels were

expressed as adducts/1Q9 nucleotides.

mRNA expression. mRNA levels in the lung tissues were determined by qPCR.

Briefly, cDNA was synthesized by using High Capacity Reverse Transcription kit
(Applied Biosystems, Foster City, CA). Polymerase Chain Reaction primers for
CYPIAI, CYPIBI, EphxI, UGTIAI, UGTIA6, SULTIAI, GSTMI, ERCC5, ERCC6,
XPC and

~-Actin

were designed using Primer Express (Version 3.0, Applied Biosystems,

Foster City, CA). Primer sequences for 18S RNA was obtained from literature (123). The
primer sequences were as follows:
Amp
Forward primer

Reverse primer

(bpJ

CYPIAI

5'-TGGAGACCTTCCGACATTCAT-3'

5'-GGGATATAGAAGCCATTCAGACTTG-3'

88

CYPIBI

5' -AACCCAGAGGACTTTGA TCCG-3'

5' -CGTCGTTTGCCCACTGAAAA-3'

101

Ephxl

5'-ACTTACACATCCAAGCCACCAA-3'

5'-GGCCCACGGGAGAGTCA-3'

66

UGTlAI

5' -ACACAGA TCGCATGAACTTCCTG-3'

5' -AGGACTCAGAAGGTCCTTGACAGTC-3'

151

UGTlA6

5' -AGACCACATGACATTTCCCCAA-3'

5' -AGAGTTCTGGTGTAAGGCAGGTAGG-3'

151

SULTIAI

5' -AGCTGAGACACACTCACCCTGTT-3'

5' -ATCCACAGTCTCCTCGGGTAGA-3'

122

5' -TCTTGACCAGTACCACA TTTTTGAG-3'

5'-TCGAAAATATAGGTGTTGAGAGGTAGTG-3'

143

GSTMI
ERCC5

5' -GCCGTGGATATTAGCA TTTGG-3'

5'-GGAGCATCACCATCAAATACAAAA-3'

161

ERCC6

5'-CTCCAATGCTTCCCCAGTACA-3'

5'-CGGGTTTATCGTGTCTCTCAAGA-3'

73

5' -GGAGGAGGTGGAAGAACTT ACTGA-3'

5'-CCGCGAGGTAGCAGAATTTT-3'

64

5'-GGGAGGTAGTGACGAAAAATAACAAT-3'

5'-TTGCCCTCCAATGGATCCT-3'

101

5' -GCCAACCGTGAAAAGATGAC-3'

5'-ACCCTCATAGATGGGCACAG-3'

165

XPC
18S-RNA
p-Actin

All primer pairs have been tested for their amplification efficiency.

~-Actin

and I8S

RNA were determined to be good reference genes in this study. Polymerase chain
reaction was performed with a 7500 Fast Real-time PCR System (Applied Biosystems,
Foster City, CA). The comparative CT method was used to determine the difference in
mRNA expression between samples by normalizing to housekeeping genes
I8S-RNA). The fold differences were calculated as (2'MCt).
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(~-actin

and

Western blotting. 10% SDS polyacrylamide gel was used for separation of
microsomal and cytosolic proteins (12 J-lg each)/well. Proteins were transferred to
polyvinylidene difluoride (PVDF) membranes. After co-incubation with primary and
secondary antibodies, detection of proteins was performed using an ECL plus detection
kit (Amersham Biosciences, Piscataway, NJ). Primary antibodies were anti-CYPIAI
rabbit polyclonal IgG (1:2000), anti-CYPIBI rabbit polyclonal IgG (1:2000), GSTMI
rabbit polyclonal IgG (1:400), UGTIA mouse monoclonal IgG (1:2000) and anti-betaactin mouse monoclonal antibody (1 :4,000). All secondary antibodies were used at
1:3,000.

Enzymatic activities
CYPIAI and CYPIBl. The assay was performed using the conditions described
(124, 125). Briefly, the reaction mixture contained 100 mM potassium phosphate, pH 7.6,

5 J-lM ethoxyresorufin, 25 J-lg of microsomal protein and 250 J-lM NADPH. Excitation
wavelength of spectrometer was set at 530 nm and emission at 585 nm. Readings were
taken immediately after the addition of NADPH and continued for over 30 min. The
activity was calculated from the linear portion of the plot.
GST activity. The activity was measured spectrophotometric ally as described (125,
126). Briefly, the reaction mixture contained 100 mM potassium phosphate, pH 6.5, 1
mM l-chloro-2,4-dinitrobenzene, 5 J-lg of cytosolic protein and 5 mM reduced

glutathione. Absorbance was measured at 340 nm. Readings were taken immediately
after the addition of reduced glutathione and continued for over 40 min. The activity was
calculated from the linear portion of the plot.
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Plasma levels of Poly E catechins by LCIMS. Quantification of poly E catechins
was performed using LC/MS. Plasma sample preparation followed the literature (76).
Briefly, 200 III plasma was mixed with 10.5 III of glacial acetic acid and 20 III of a
mixture of

~-glucuronidase

(2,000 units) and sulfatase (43 units) (Sigma-Aldrich, St.

Louis, MO) and incubated at 37°C for 45 min. The reaction mixture was extracted with
dichloromethane followed by ethyl acetate extraction twice. Ten III of 2.5% ascorbic acid
was added to the combined ethyl acetate extracts. The mixture was lyophilized and the
residue was dissolved in 40 III 8% acetonitrile. LCIMS was performed by Accela LC
from Thermo Scientific (San Jose, CA) with a Hypersil GOLD 50 x 2.1 mm C18 column.
A 15 min gradient with 5% acetonitrile/O.l % formic acid (Solvent A) and 95%
acetonitrile/O.l % formic acid (Solvent B) at 0.1 ml/min was used. The gradient started
from 5% Solvent B that increased linearly to 50% in 12 min and then increased linearly
to 75% in 3 min. Elute from LC was coupled to a LTQ Orbitrap XL mass spectrometer
(Thermo Scientific, San Jose, CA) via an ESI source. MS and MSIMS spectra were
acquired in positive ion mode at 30,000 mass resolution. Plasma from untreated animals
served as blank. Blank plasma spiked with 1,2,5,10,25,50, 100,200,400 pmol of each
catechin standards (EGC, EC, EGCG and ECG), along with 50 pmol quercetin as an
internal standard, were used to generate a calibration curve.

Tissue levels of GTPs by LCIMS. Lung tissue (200 mg) was mixed with 0.84 ml
of PBS and 40 III of glacial acetic acid and homogenized. After centrifugation (16,000g, 6
min), 0.62 ml of the supernatant was processed essentially as described above for plasma
GTP levels.
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Statistical analysis. Results are reported as mean ± SD. Generalized linear model
(GLM) was used to investigate the effect of treatment and time. SARS v.9.2 was used for
statistical analyses. A p-value less than 0.05 was considered statistically significant.

Results:
In vitro release of poly E from the implants. Agitation of poly E polymeric
implants in PBS in the presence of serum showed a continuous release of the poly E
catechins from the implants. There was a burst release initially and then it declined
slowly but continuously. For example, more than 3.6 mg catechins were released on day
1 before declining to nearly 0.27 mg daily release on day 7, thus an exponential decrease
occurred as a function of time (Figure 4-1). The cumulative release after 7, 28 and 56
days were 19%, 26% and 29% of the initial amount, respectively. In a separate study I
determined that poly E was unstable in the aqueous environment degrading by 58% over
24-h period. Therefore, the above data of catechin release have been corrected by
multiplying with the factor 2.38.

Effect of poly E on BP-induced DNA adduct levels and its rate of release and
stability in vivo. Treatment of SID rats with a subcutaneous BP implants produced two
major DNA adducts in the lung (Figure 4-2A-b); no adducts spots were detectable in
sham-treated animals (Figure 4-2A-a). These adducts have been characterized previously
as derived by interaction of deoxyguanosine (127) with anti-BP-7 ,8-diol-9, lO-epoxide
(anti-BPDE) (adduct 1) (20) and 9-0H-BP-3,4-epoxide (9-0H-BP) (adduct 2) (115).

Both adducts were found to have similar adduct levels in lung tissue following 1 week of
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BP treatment, 11.8 ± 5.2 adducts/1Q9 nucleotides for BPDE-derived and 13.8 ± 4.5
adducts/l09 nucleotides for 9-0H-BP-derived adducts. The total adduct levels increased
modestly by 20% from 1 week (25.6 ± 3.9 adducts/1Q9 nucleotides) through 4 weeks
(31.1 ± 5.2 adducts/1Q9 nucleotides) of BP treatment (Figure 4-2). Adduct levels of both
BPDE- and 9-0H-BP-derived adducts increased proportionately with time indicating that
both adducts accumulated at similar rates.
Intervention with Poly E administered by the implant route (12.9 ± 2.3 adducts/l09
nucleotides) resulted in a significant reduction (50% decrease; p=0.023) of total adduct
levels after 1 week of BP treatment (Figure 4-2Bl); the levels of both adducts were
diminished similarly. The implant route of poly E administration was also effective in
reducing the adduct burden after 4 weeks. Anti-BPDE-dG adduct levels were
significantly reduced (35%) while 9-0H-BP-dG adduct levels were decreased (20%) but
the reduction was statistically insignificant (Figure 4-2B2). Poly E administered via the
drinking water modestly (34%) diminished the total adduct burden after 1 week, with
similar effects on both adduct levels, however, this decline was not significant (p=0.20)
(Figure 4-2Bl); the effect of poly E via the drinking water route after 4 weeks was not
investigated.
There was no significant difference in either the body weight or the lung and liver
weights between any of the groups (data not shown) suggesting that BP or poly E
administration, irrespective of the route of administration, had no detectable adverse
effects.
To determine if poly E catechins embedded in the polymeric matrix were stable
during the course of the treatment, extracts of the implants recovered from the animals
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were analyzed by HPLC. Analysis of the extracts from implants before and after the
animal treatment and their comparison with reference catechins at a wide range from 250
to 650 nm UV absorption showed no qualitative difference in the major catechins
detected in the implant extracts (Figure 4-3), indicating that the catechins remained stable
in the implant during the preparation of implants as well as during the course of the study

in vivo.
To determine the total dose of poly E administered via the implants, I measured the
residual amount of poly E in the implants recovered from the animals. The total dose
administered via the drinking water was estimated based on the approximate daily water
intake. Comparison of the total dose administered during the course of the 1 week study
via the implants (15.7 mg) and the drinking water (1,632 mg) indicated that the oral dose
was over 100-fold higher than the implant route. Additionally, the doses of poly E
released from implants in vivo (15.7 mg) and in vitro (15.2 mg) at 1 week time point are
in excellent agreement, indicating that the in vitro release system can predict the in vivo
rate of release of poly E catechins.

Plasma levels of GTPs. The calibration curve generated by spiking plasma from
untreated animals with 1, 2, 5, 10, 25, 50, 100, 200,400 pmol of each reference catechin
(EGCG, ECG, EGC, EC) and 50 pmol of quercetin as an internal standard was found to
be linear in this range (R2 > 0.997 for all compounds tested).
There were no detectable GTPs in animals (groups 1, 2 and 3) without any poly E
treatment based on the LC/MS analysis of the plasma samples. However, animals treated
with poly E implants for 1 week clearly showed the presence of all the four GTPs in the
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plasma samples (Figure 4-4), with EGCG predominating (Table 4-1). In the drinking
water group, however, EGC and EC were found at significantly higher levels (Table 4-1).
The plasma levels of EGCG in the implant (60.6 ± 25.4 ng/ml) and drinking water (96.9
± 43.9 ng/ml) groups were not significantly different. EGCG was also the most

prominent GTP detected after 4 weeks of poly E implantation; however, the levels were
lower compared with one week treatment (Table 4-1).

Tissue levels of GTPs. The detection limits for EGCG, EGC, EC and ECG were
established first in the lung tissue environment and found to be approximately 1, 3, 3 and
4 ng/g, respectively. Lung levels of EGCG at 1 week time point were found to be 17.2 ±
8.50 and 19.8 ± 6.87 ng/g tissue in animals treated with poly E via implants (Group 4)
and drinking water (Group 5), respectively. However, none of the other catechins EGC,
EC and ECG were detected in the lung tissue presumably they were below the detection
limits.

Effect of poly E on xenobiotic-metabolizing and DNA repair enzymes in lung
tissue. Compared with sham treatment, BP treatment by low-dose continuous exposure
resulted in substantial overexpression of CYPIAI (192 ± 8.5 fold) and CYPIBI (15 ±
1.2 fold) after I week as determined by qPCR. The effect on CYPIAI expression after 4
weeks was even more pronounced (852 ± 25.9 fold) though the effect on CYPIBI
expression (8 ± 0.68 fold) was less pronounced (Figure 4-5). Poly E administration alone
or together with BP treatment showed no significant effect on the expression of the
selected phase I enzymes (CYPIAI, CYPIBI and Epxhl), phase II enzymes (UGTIAI,
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UGTlA6, SULTlAl and GSTMl) or DNA repair enzymes (XPC, ERCC5 and ERCC6)
(Figure 4-5).
Consistent with the findings at the mRNA level, sham implant treatment did not
affect the expression of CYPlAl, CYPlBl, UGTlA and GSTMl at the protein levels.
However, treatment with BP implants showed higher levels of CYPlAl and CYPlB 1
after 1 week of BP treatment consistent with their overexpression at the mRNA levels.
These proteins still remained overexpressed following 4 weeks of

BP treatment

compared with sham treatment, though the levels were less pronounced; poly E
administration alone (group 6) showed no significant effects on any of the phase I and
Phase II enzymes studied (Figure 4-6).
At the activity level also, BP treatment greatly induced the activity of CYPlAl and
CYP 1B 1 compared with sham treatment in the lung microsomes consistent with their
overexpression at the mRNA and protein levels. However, no significant inhibition of the
activity was observed by poly E administered by implants together with BP. The
enzymatic activity was, in fact, significantly increased (p=O.035) by poly E when
administered via the drinking water together with BP implant (Table 4-2). No significant
change in the GST activity was observed following any of the treatment given
individually or in combination (Table 4-2).

Discussion:

GTPs have been shown to have significant chemoprotective activity using in vitro
models, however, their efficacy in vivo is inconsistent. A primary limiting factor of this
discrepancy is believed to be lack of oral bioavailability of GTPs. In this study we have
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investigated the application of a novel sustained-release system Via subcutaneous
polymeric implants in rats by poly E containing a mixture of GTPs as an alternative to the
oral administration of these chemoprotective compounds to increase their bioavailability
and efficacy in vivo. The rate of release of GTPs from these polymeric implants was first
studied in vitro using a mock environment to mimic the in vivo situation in order to
establish a baseline for further in vivo evaluation. In vitro release of the GTPs from the
poly E implant, as measured spectrophotometric ally, showed a continuous decline with
time. This observation in the initial release appears to be a simple diffusion process. The
surface-bound GTP molecules were readily released from the implant as the rate of
release was inversely proportional to the square of the distance between the molecules
and the implant surface. In this sense, surface-bound drug of the implants is released
more readily compared with the drug molecules embedded in the inner layers of the
implant. Further, GTPs are not stable under alkaline or near neutral pH, mainly because
of oxidation at these pHs. In the in vitro release experiment, degradation of the GTPs
occurs as they are released from the implants and enter into in the surrounding medium
(PBS with 10% bovine serum). In this study the rate of degradation of the GTPs was
determined separately and the rate of release was adjusted using a correction factor.
Although degradation of the GTPs occurs following their release from the implant, no
degradation was observed during preparation of the implant due to the stability of GTPs
in the organic solvents used in the preparation process. Once the GTPs are embedded in
the

polymeric

matrix,

they

are

sheltered

from

any

aerobic

oxidation.

BP treatment was also provided by subcutaneous polymeric implants in order to
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provide a continuous low-dose carcinogen exposure instead of a bolus dose as this would
represent a more realistic in vivo exposure situation.
Previous studies have indicated that green tea and its bioactive components have
protective effects against PAH-mediated DNA damage and carcinogenesis, including BP.
Preparations of green tea, administered during or after PAH exposure, have been shown
to decrease tumor incidence and multiplicity in animal models including mouse
forestomach and lung (50), mouse transplacental lung tumors (128), mouse skin (129)
and hamster buccal pouch (130). Inhibition of PAH-mediated DNA damage (106, 129),
including my own studies (131) and mutagenesis (132) have been shown to mediate
green tea's antitumorigenic and anticarcinogenic effects. In this study, the GTPcontaining poly E implants were found to be more effective in reducing BP-induced
DNA adducts in rat lung tissue following a 1 week exposure, compared to poly E
administered via the drinking water (50% versus 34% reduction). More importantly, I
determined that the total dose of poly E administered via the implants was > 100 times
lower than that administered by the oral route (15.7 mg versus 1,632 mg). This
observation strongly supports my hypothesis that delivery of GTPs by subcutaneous
polymeric implants decreases the effective dose dramatically while eliciting an equal to
or greater biological effect. Bioavailability of EGCG was also found to be improved by
transdermal delivery compared to oral dosing (133). Poly E implants also continued to be
an effective inhibitor of BP-induced DNA adduct formation following 4 weeks of
exposure of the rats to continuous low doses of BP. However, the DNA adduct inhibition
activity was reduced compared to the 1 week treatment, presumably due to decreased
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release of the GTPs from the implants; the poly E effect via the drinking water route after
4 weeks was not investigated.
In order to further investigate the mechanism(s) of poly E's observed BP-induced
DNA adduct inhibition,

analysis of several enzymes involved in PAH metabolic

activation (CYPIAI, CYPIBI and Ephxl) and detoxification (UGTIAl, UGTIA6,
SULTIAI, GSTMl) as well as others involved in nucleotide excision repair (ERCC5,
ERCC6, XPC) was conducted. Reports from cell culture studies have shown that green
tea extracts can act as an agonist of the AhR and induce the expression of CYPIA at the
mRNA and protein levels (134, 135), while simultaneously as an antagonist to inhibit
CYPlA expression induced by TCDD (134). GTPs are also known to inhibit the activity
of CYPIA in liver micro somes isolated from phenobarbital and 3-methylcholanthrene
treated rats (136). However, other studies suggested that the effect of GTPs on P450
monooxygenase varies with cell type (137) and tissue type (138). Many confounding
factors, including but not limited to, the differences in composition of GTP preparations
in various studies, in vitro versus in vivo administration routes and dosage may contribute
to the observed inconsistence. Presumably due to similar reasons, there were conflicting
reports of the effect of GTPs effects on phase II enzymes such as GST (130, 139, 140).
In this study, continuous exposure to low dose BP via polymeric implants dramatically
increased the expression of CYPlAl and lBl at both mRNA and protein levels, while
having no effect on GSTM 1 expression. In agreement with this, the enzyme activity of
CYPl, but not GST was significantly higher following BP implant treatment. Poly E,
administered via the drinking water, but not by the implants, was found to further
increase CYPI enzymatic activity induced by BP, which may, in part, account for the
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decreased efficacy of the oral exposure route as compared to the implant route regarding
the inhibition of DNA adduct formation between these two groups. However, with the
exception of CYPI enzymatic activity, poly E, administered either by implant or orally,
had no effects on the expression or activity of any of the metabolizing or DNA repair
enzymes studied, suggesting that poly E inhibits BP-induced DNA adduct formation
through non-enzymatic pathways. One likely pathway for the inhibition of BP-induced
DNA damage is direct binding of the electrophillic metabolite of BP with the adjacent
hydroxyl groups of the green tea polyphenols. In a recent study published from this
laboratory (131), a correlation between the number of adjacent aromatic hydroxyl groups
in the structure of various GTPs and hydrolyzable tannins and their potencies for
inhibiting BP-induced DNA adduction was found. Further, electospray ionization mass
spectrometry and liquid chromatography-mass spectrometry analysis confirmed the direct
covalent interaction of the hydroxyl groups of a model GTP, EGCG, with anti-BPDE, the
ultimate carcinogenic metabolite of BP. EGCG is the most active and also the most
abundant component in poly E. The biological effects in this experiment are hypothesized
to be predominantly mediated by EGCG and possibly ECG albeit to a lesser degree. The
dramatic difference in plasma levels of EC and EGC in the poly E implant group and
drinking water group at the 1 week time point reflects the large difference (> 100 times
fold) in the total dose administered, as noted previously, while the absorption of EC and
EGC from the digestive tract is relatively high (31.2% and 13.7%, respectively as
reported) (72). The plasma level of EGCG is comparable between these two groups
despite the large dose difference, presumably due to the relatively poor digestive
absorption of EGCG (0.1 %) (72). Considering the short half lives «3-4 h) of these
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catechins in vivo (72), the plasma level of the catechins primarily reflects the poly E
released into blood stream by the implant or absorbed from the digestive tract on the last
day or even a shorter time duration. The release profile from the implants in vitro might
mimic the in vivo release pattern, so it is reasonable to speculate that the plasma
concentration of GTPs in the implant group may be higher initially. In the drinking water
group, the plasma concentration of GTPs somewhat fluctuated based on the water intake.
The significant reduction in the DNA adduct levels observed after 7 d by poly E implants
seem to result from its cumulative release during the 7 day period, not from just the i

h

day. This notion may also explain the higher degree of adduct inhibition observed in the
implant versus the drinking water groups.
In conclusion, my study demonstrates that sustained systemic delivery of GTPs by
subcutatneous polymeric implants decreases the effective dose dramatically while
eliciting a greater biological effect as compared to the traditional oral route. Further,
mechanistic studies of poly E, at submicromolar plasma levels achieved in this study,
suggest that its efficacy at inhibiting BP-induced DNA damage was not a result of
modulation of metabolic or DNA repair pathways but from direct scavenging of the
electrophillic metabolites. Thus, subcutaneous polymeric implants may provide a novel
viable sustained release system for chemopreventive/chemotherapeutic agents with poor
oral bioavailability such as GTPs.
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Table 4-1. Plasma concentrations of individuals GTPs in SID rats treated with
polyphenon E (poly E) via polymeric implants or the drinking water together with
benzo[a]pyrene implant for indicated periods. Poly E catechin levels were measured by
LC-MS.
Plasma poly E catechin levels (ng/rnl)
Poly E
BP implant + poly E

BP implant + poly E in

BP implant + poly E

implants (1 wk)

drinking water (1 wk)

implants (4 wk)

EGC

13.3 ± 3.8

277.8 ± 225.3*

7.2± 1.5

EC

8.8 ± 2.6

336.5 ± 300.9*

3.4 ± 0.3

EGCG

60.6 ± 25.4

96.9 ± 43.9

15.2 ± 6.3

ECG

8.2 ± 4.3

15.8 ± 8.3

0.9 ± 0.9

catechins

P<0.05
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Table 4-2. Enzymatic activity of CYPI and GST following treatment of SID rats with
benzo[a]pyrene (BP) implant or polyphenon E (poly E) implants or combination.
CYPI activity

GST

activity

(fold change)

(fold change)

BP implant

38.74 ± 7.69

1.17 ± 0.14

BP implant + Poly E implant

41.21 ± 6.37

1.18±0.17

51.15 ± 8.89a

1.21 ±0.11

Poly E implant

0.61 ±0.11

1.23 ± 0.03

BP implant

33.72 ± 12.39

1.34 ± 0.20

BP implant + Poly E implants

23.28 ± 7.88 b

1.23 ± 0.22

Treatment

1 week

BP implant + Poly E in drinking
water

4 week

Enzymatic activity was expressed as fold change of sham treatment.
a

p<0.05 (BP implant + Poly E in drinking water group versus BP implant group at 1

week)
b

p<0.05 (BP implant + Poly E implant 1week versus 4 week)
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four-week BP implant + polyphenon E implants. 1, anti-benzo[a]pyrene-7,8-diol-9,10epoxide-dG; and 2, 9-0H-benzo[a]pyrene-4,5-epoxide-dG. B 1: DNA adduct levels after
1 week; and B2, DNA adduct levels after 4 weeks. *p<O.05.
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treatment; Group 2, Sham implants; Group 3, BP implant; Group 4, BP implant + poly E
implants; Group 5, BP implant + poly E in drinking water; and Group 6, Poly E implants.
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CHAPTER V: EFFICACY AND POTENTIAL MECHANISMS OF GREEN TEA
POLYPHENOLS AS AN ADJUVANT TREATMENT TO CISPLATIN·BASED
LUNG CANCER THERAPY

Introduction:
In the United States, lung cancer is the second most common cancer type in men
and women, only less than prostate cancer in men and breast cancer in women. However,
lung cancer accounts for the highest cancer-related deaths (120). Effective prevention and
treatment strategies are therefore urgently needed.
Currently, chemotherapy is one of the most import strategies in the treatment of
lung cancer. To maximize the efficacy and minimize the side effects and toxicity of
chemotherapeutic drugs, a combination of two or more chemotherapeutic drugs is often
necessary. Based on multiple randomized clinical trials and meta-analyses, cisplatinbased chemotherapy is more preferred over other combinations if it is effective (141).
The basic principle of combination chemotherapy is to select drugs with differing
mechanisms of action, toxicity and side effect profiles in order to augment their efficacy
and decrease their toxicity (78).
Green tea is one of the most popular drinks in the world. It is now drawing more
attention because of its possible chemoprotective effects (41, 50-54). The possible
mechanisms of action of green tea catechins have been extensively studied in vitro. GTPs
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were found to induce apoptosis in cancer cells and inhibit the proliferation of a variety of
cancer cells types in vitro, including lung cancer cells (45-49). GTPs can inhibit
epidermal growth factor (EGF), hepatocyte growth factor (HGF) and fibroblast growth
factor 2 (FGF2) dependent signaling pathway, and interfere with enzyme activities of
JUK, JUN, MEKl, MEK2, EKl, EK2, CDK2 (57). They have also been shown to be
highly potent antioxidants (58). Under certain conditions, GTPs can generate some types
of reactive oxygen species, including hydrogen peroxides which are believed to help to
kill cancer cells (59, 60).
Edible berries have demonstrated many biological effects in cardiovascular
disorder, degenerative diseases, inflammatory responses and cancer intervention (142144). Anthocyanidins presented in berries are responsible for the red, purple and blue
color of these fruits. Studies have shown that diet supplemented with black raspberry
powder inhibit azoxymethane-induced colon cancer and N-nitrosomethylbenzylamine
(NMBA)-induced esophageal tumorigenesis (145, 146).

Cherry anthocyanidins were

able to inhibit tumor development in APC (min) mice (147, 148). These anthocyanidins
are potent antioxidants as GTPs. They were found to inhibit proliferation and promote
apoptosis of various cancer cell lines (149), decrease the expression of matrix
matalloprotinase (MMP-2)

and urokinase-plasminogen

activator (u-PA), inhibit

activation of c-Jun and NF-kappaB (150).
Based on these studies the mechanisms of action of GTPs and anthocyanidins
appear to be different from known chemotherapeutics including but not limited to
cisplatin, carboplatin, paclitaxel, docetaxel, doxorubicin, gemcitabine and vinorelbine
(79-85). For example, cisplatin and carboplatin exert their effects through crosslinking

87

with DNA and form DNA adducts (79, 80); paclitaxel and docetaxel are anti-microtubule
agents (81, 82); gemcitabin is a nucleoside analog and an anti-metabolite (84); etoposide
is a topoisomerase II inhibitor (86); irinotecan and topotecan are topoisomerase I
inhibitors (87, 88). This mechanistic difference between GTPs, anthocyanidins and the
standard chemotherapeutics currently used to treat lung cancer follows the principle of
combination treatment. Importantly, the application of GTPs and anthocyanidins is
relatively safe since it exhibits little to no toxicity or deleterious side effects in vivo (55).
In this study, I investigated the effects of these natural compounds as a neoadjuvant treatment in combination with known chemotherapeutics including cisplatin,
carboplatin, paclitaxel, docetaxel, doxorubicin, gemcitabin, vinorelbin, etoposide and
topotecan in cell culture. The effects of these combinations are various. One of the most
promising combinations, which is GTPs, anthocyanidins and cisplatin, was further tested
in vivo using a xenograft nude mouse model. The possible mechanisms of action of the

combination therapy were also studied.

Materials and Methods:
Chemicals
EGCG was purchased from LKT laboratories, Inc. (St. Paul, MN, USA).
Polyphenone E (poly E) was a gift from Pharma Foods International Co., Ltd (Kyoto,
Japan). Anthocyanidins used in cell culture including delphinidin, cyanidin, malvidin,
peonidin, petunidin were obtained from ChromaDex Inc. (Irvine, CA, USA).
Anthocyanidins used in animal study were isolated from highly enriched bilberry extract
by the laboratory of Dr. Inder Pal Singh, NIPER, Mohali, Punjab, India under a
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collaborative arrangement. The anthocyanidins isolated contained 32.5% delphinidin,
28.6% cyanidin, 15.4% malvidin, 15% petunidin and 5% peonidin as analyzed by HPLC.
Cisplatin, carboplatin, paclitaxel, docetaxel, doxorubicin, gemcitabine, vinorelbine,
etoposide, topotecan, quercetin, withaferin A, plumbagin, curcumin, resveratrol,
cucurbitacin B, celastrol, ethidium bromide and acridine orange were purchased from
Sigma-Aldrich (St. Louis, MO, USA). Apoptosis kit with Annexin V Alexa Fluor 488
and PI for flow cytometry was purchased from Invitrogen Corporation (Carlsbad,
California, USA). Rabbit anti-Bcl-2, anti-Bax, anti-cyclin Bl, anti-cyclin Dl, anti-cdc2,
anti-p21 primary antibody and anti-rabbit HRP-linked secondary antibody were
purchased from Santa Cruz Biotech (Santa Cruz, CA). Rabbit anti-PARP antibody was
from Cell Signaling Technology, Inc. (Danvers, MA, USA). Mouse anti-B-actin antibody
was from Sigma-Aldrich (St. Louis, MO). Mouse anti-PCNA primary antibody and antimouse secondary antibody was from Cell Signaling Technology (Danvers, MA). Other
reagents used were from the following sources: Pierce® BCA Protein Assay Kit (Thermo
Fisher Scientific, Rockford, IL.), and ECL plus detection kit (Amersham Biosciences,
Piscataway, NJ).

Cell culture

The human non-small cell lung cancer cell line, H1299, was obtained from ATCC.
Cells between 5-20 passages were used and cultured in Glutamax medium containing
10% fetal bovine serum (FBS) and 1% penicillin-streptomycin. Cell cultures were
incubated at 37°C in a humidified atmosphere with 5% CO 2 •
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MTT assay
H1299 cells (5 x 103) were seeded in 96-well plate and received EGCG,
anthocyanidins, EGCG plus anthocyanidins, cisplatin or EGCG/anthocyanidins/cisplatin
the second day following seeding. After incubation for 48 hrs, the culture medium was
replaced and 10 III of MTT (5 mg/ml in PBS) was added in each well for additional 3 hrs
at 37°C, the medium was discarded and replaced by 100 III of DMSO. Absorbance was
determined by a SpectrMax M2 (Molecular Devices, Sunnyvale, CA) at 570 nm (151).

Cell cycle and apoptosis analysis by flow cytometry
2 x 105 cells were seeded in 60 mm culture dishes and received either vehicle,
cisplatin, EGCG plus anthocyanidins (delphinidin, cyanidin, malvidin, peonidin,
petunidin) alone, or cisplatin in combination with EGCG and anthocyanidins the second
day. Cells were lifted after incubation for 48 hrs and washed with PBS. For cell cycle
analysis, cells were fixed in 70% ethanol and stained with PI only and measured by BD
FACSCalibur flow cytometer (BD Biosciences, San Jose, CA). For apoptosis analysis,
cells were re-suspended in binding buffer and stained with 5 III of Annexin Alexa Fluor
488 (Invitrogen Corporation, Carlsbad, California) and 1 III of PI for 15 min at room
temperature and diluted with binding buffer before being measured by flow cytometry.
Data were analyzed using FlowJo software (Tree Star Inc., Ashland, OR, USA).

Ethidium bromide/acridine orange staining
1 x 105 cells/well were seeded in a 6-well plate culture dish and received either
vehicle, 7.5 flM of cisplatin, EGCG plus anthocyanidins (delphinidin, ocyanidin,
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malvidin, peonidin, petunidin) alone (7.5
~M

EGCG and anthocyanidins (7.5

~M

each)

each) or cisplatin in combination with

the second day. After 48 h, cells were

detached and washed with PBS and re-suspended in 25
with 2

~l

~l

of PBS followed by staining

of ethidium bromide (100 I-lg/ml) and acridine orange (100 I-lg/ml). Cells were

viewed using a Nikon Eclipse 80i microscope (Nikon Instruments Inc., Melville, NY )
and pictures were taken with a Nikon Digital Sight camera (152).

Western blotting

5 x 105 cells were seeded in a 100 mm culture dishes and received either vehicle,
~M

7.5

of cisplatin, EGCG plus anthocyanidins (delphinidin, cyanidin, malvidin,

peonidin, petunidin) alone (7.5
anthocyanidins (7.5

~M

~M

each) or cisplatin in combination with EGCG and

each) the second day. After 48 h, cells were harvested using

RIPA buffer. Protein was quantified with Pierce® BCA Protein Assay Kit (Thermo
Fisher Scientific, Rockford, IL.). 10% SDS polyacrylamide gel was used for protein
separation (30

~g/well).

Proteins were then transferred to polyvinylidene difluoride

(PVDF) membranes. After co-incubation with primary and secondary antibodies,
detection of proteins was performed using an ECL plus detection kit (Amersham
Biosciences, Piscataway, NJ). The concentration of anti-cyclin Bl and anti-p21 primary
antibodies was 1:500,

anti-~

actin was 1: 3000, and all others were 1: 1000. The

concentration of secondary antibodies was 1: 1000 for detection of cyclin B I, p21, 1:5000
for

~

actin and 1:2000 for the rest.

Animal handling
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Six week-old female nude mice were purchased from Charles (Indianapolis, IN).
After acclimation for 7 d, animals were inoculated with 1 x 106 H 1299 cells with matrigel
on the left flank side. After tumor size reached approximately 30 mm3 , animals were
randomized and treated with poly E, anthocyanidins, cisplatin alone or in combination as
in Table 5-1. Poly E was administered by intraperitoneal injection (O.lml of 10 mg/ml
poly E solution in H20 containing 1.0% DMSO, every other day) or by polymeric
implants (one, 1.5 cm implant containing 20% polyE). Anthocyanidins were given i.p.
(O.lml of 5 mg/ml bilberry extract solution in H20 containing 1.0% DMSO, every other
day). Cisplatin was administered i.p. (0.1 ml of lmg/ml solution in PBS) once a week for
5 times. Body weights and tumors were measured weekly. Animals were euthanized after
5 weeks. Blood was taken by cardiac puncture. Skin tissue was fixed in 10%
formaldehyde and removed to 70% ethanol before further processing. Tumor tissues were
harvested for western blotting following the same protocol mentioned previously in the
western blotting section except the protein loading is 50 Ilg/well. The concentrations of
primary antibody and secondary antibody remained the same.
All animal experiments were performed after seeking approval from the
Institutional Animal Care and Use Committee (IACUC).

Results:
MTT assay for EGCG in combination with other phytochemicals

The MTT assay was conducted in order to assess the effects of various treatments
on cell viability and proliferative activity in human lung cancer cells H1299. Firstly, a
serial concentration of EGCG was used to determine the IC so of EGCG, which was found
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to be approximately 20 IlM. At 10 IlM, EGCG showed only a moderate effect (10%
antiproliferative activity). Secondly, a serial concentration of anthocyanidins (comprised
of an equal molar concentration of the following: delphinidin, cyanidin, malvidin,
peonidin, petunidin), quercetin, withaferin A, plumbagin, curcumin, resveratrol,
cucurbitacin B, celastrol alone or in combination with 10 IlM of EGCG were tested for
their effect on cell proliferation and viability. The results showed that EGCG enhanced
the antiproliferative activity of the anthocyanidin mixture and plumbagin, but not the
others (Figure 5-1). The antiproliferative activity of EGCG-anthocyanidins was
determined to have an IC so concentration of 6 !AM. This value was found to be 2- and
3.3-fold lower compared with anthocyanidins (12 IlM) and EGCG (20 IlM) alone,
respectively.

MTT assay for EGCG in combination with chemotherapeutics
A serial concentration of cisplatin, carboplatin, paclitaxel, docetaxel, doxorubicin,
gemcitabine, vinorelbine, etoposide and topotecan alone or in combination with 10 IlM of
EGCG were tested using MTT assay to assess cell viability of the human lung cancer
cells H 1299 following combination treatment with EGCG and these chemotherapeutics.
The results showed that EGCG does not enhance the antiproliferative activity of any of
these chemotherapeutics (data not shown).
However, when the mixture of EGCG and anthocyanidins (delphinidin, cyanidin,
malvidin, peonidin and petunidin) was combined with cisplatin, the anitproliferative
activity of cisplatin was found to be enhanced significantly. The IC so of cisplatin alone
was found to be :::::50 IlM. However, when combined with the EGCG-anthocyanindin
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mixture (10 flM each), the IC so of cisplatin was significantly reduced «3 flM) (Figure 52).

Cell cycle analysis of cisplatin in combination with EGCG plus anthocyanidins
Cell cycle analysis was conducted in order to assess the effects of various
treatments on cell cycle in human lung cancer cells H1299. Cells were treated with either
vehicle (0.5% DMSO), 10 IlM of cisplatin, 10 IlM of EGCG- anthocyanidins or 10 IlM
of cisplatin plus EGCG- anthocyanidins. The result showed that 46.7% of the cells
treated with the vehicle alone were in G 1 phase and 31.1 % and 21.5% of the cells were in
S or G2 phase, respectively. After treatment with cisplatin, the number of cells in the G 1
phase dropped to 25.8% while the number of cells in the G2 phase increased to 53.7%,
suggesting that the cisplatin initiated a G21M arrest. In contrast, cells treated with the
EGCG-anthocyanidin mixture, exhibited no significant change in cell cycle distribution
compared with vehicle treated cells, 50%, 26.9% and 21.2% in Gl, Sand G2 phase
respectively. The effect of cisplatin in combination with EGCG plus anthocyanidins was
similar to the effect of cisplatin alone, 24.5% in Gland 56.5% in G2 phase (Figure 5-3).

Apoptosis analysis of cisplatin in combination with EGCG plus anthocyanidins
Apoptosis analysis was conducted in order to assess the effects of various
treatments on apoptosis in human lung cancer cells H1299. In initial analysis, 10 IlM
cisplatin did not cause significant apoptosis, therefore, cells were treated with either
vehicle (0.5% DMSO), 25 IlM of cisplatin, 10 IlM of EGCG- anthocyanidins or 25 IlM
of cisplatin plus EGCG- anthocyanidins. The results are depicted in Figure 5-4. In the
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vehicle treated group the apoptotic cells and dead cells were 6.67% and 3.04%
respectively, total of 9.71 %. These levels increased following treatment with cisplatin to
12.9% apoptotic cells and 17% dead cells yielding a total of 29.9%. In the EGCG plus
anthocyanidins group, the apoptotic cells accounted for 17.4% and dead cells, 9.48%, for
a total of 26.88%. Treatment with the combination of cisplatin and EGCGanthocyanidins resulted in a significant increase in apoptotic cells to 36.9% and dead
cells to 22.8%, for a total of 59.7%. These data indicate that the combination treatment of
cisplatinlEGCG/anthocyandins was resulted in higher levels of apoptosis and cell death
than treatment with cisplatin or EGCG-anthocyanidins alone.

Ethidium bromide I acridine orange staining
EB/AO staining was conducted to confirm the finding in flow cytometric study. No

dead or apoptotic cells were found in vehicle (0.5% DMSO) treated samples (Figure 5-5).
Further, cisplatin treatment (7.5

~M)

did not induce cell death or apoptosis. However, the

size of cells appeared to be larger than those observed following vehicle treatment,
suggesting that cisplatin may interfere with the cell cycle and cause cell cycle arrest.
EGCG plus anthocyanidins (7.5

~M)

resulted in significant apoptosis which exhibited

fragmented DNA staining with bright green or yellow. This effect was even more
pronounced in the cisplatin and EGCG plus anthocyanidins combination treatment group,
which confirms the finding in apoptosis analysis using flow cytometer.

Western blotting
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Western blotting was conducted in order to assess the effects of various treatments
on protein expression in human lung cancer cells H1299. Several molecular markers
related to cell cycle (PCNA, p21, cdc2, cyclin Bl, cyclin Dl) and apoptosis (Bax, Bcl-2,
PARP) have been investigated. The results showed that EGCG plus anthocyanidins
down-regulated the expression of PCNA, cyclin Bl, cyclin Dl and BCL-2, which are
associated with the cell survival and proliferation; while up-regulated the expression of
p21, which functions otherwise (Figure 5-6). Cisplatin treatment also decreased PCNA,
cyclin Dl and BCL-2 expression, while increasing p21 expression. However, cisplatin
treatment resulted in a significant increase of cyclin B 1 expression. The combination
treatment of cisplatin and EGCG plus anthocyanidins further decreased the expression of
cyclin Dl and Bcl-2 compared with cisplatin alone or EGCG-anthocyanidins alone
(Figure 5-6).

Xenograft nude mouse study An animal study was conducted in order to
investigate whether the findings in cell culture can be translated to in vivo. A combination
of poly E, anthocyanidins and cisplatin administered by i.p. (Group 6) significantly
decreased the tumor volume compared to that of vehicle treatment group starting from
the 1st week through the end of the study. At the 5th week, the tumor volume was
decreased by 73% (p<O.OOI) (Figure 5-7). Similarly, the combination of cisplatin-poly Eanthocyanidins in which poly E was given by polymeric implants (Group 7) decreased
tumor volume by 73% (p<O.OOI). Interestingly, other groups including poly E alone
(15%

reduction,

p>O.05),

anthocyanidins

(10%

reduction,

p>O.05),

poly

E-

anthocyanidins (6% reduction, p>O.05) and cisplatin alone group (31 %, p>O.05) did not
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show statistically significant reductions in tumor volume until the end of the study,
suggesting the efficacy of cisplatin/poly E/anthocyanidins observed from the combination
treatment may be synergistic not purely additive (Figure 5-7). Photographs of selected
animials representing each of the treatment group are shown in Figure 5-8.
All the animals in Groups 1 - 5 were active and gaining body weight throughought
the duration of the experiment. However the animals in Groups 6 and 7 appeared to
exhibit decreased activity following i.p. injections and were losing body weight (Figure
5-9). The diet intake for these animals was measured. Groups 1-5 consumed, on average,
3.9, 3.4 3.9, 3.4 and 3.6 g/animal/day, respectively. Animals in Groups 6 and 7 consumed
less diets compared with other groups, which were 2.9 and 2.6 g/animal/day,
respectively, suggesting the possible toxicity of the combination treatment.
The blood chemistry was measured as shown in Table 5-2. The blood cells were
counted as in Table 5-3. The blood analyses were conducted by Antech Dignostics (New
Hyde Park, NY). The combination treatment (Group 6) resulted in increased levels of
ALT and WBe counts in the animals tested. Also, lower glucose levels and dramatic
increased blood level of amylase and lipase were observed in these animals as well.
The skin samples of the animals in Groups 1 and 6 were fixed and HE staining was
performed thereafter. The results showed that dramatic damage of the whole layers of the
skin, including epidermis, dermis and also the subcutaneous tissue for Group 6 animals
(Figure 5-10). Fewer hair follicles and shattered fat tissues cells were also observed in
this group. Further, subcutaneous muscle layer was thinner in Group 6 comparing with
that in Group 1.
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The western blotting results of tumor tissue were consistent with the cell culture
results. Specifically, cyclin Dl decreased in the combination treatment group compared
with the vehicle treated group and other groups. Bcl-2 increased after combination
treatment (Figure 5-11).

Discussion:
The studies in this chapter were conducted to test the feasibility of using GTPs as a
neo-adjuvant treatment in the treatment of lung cancer. The MTT assay was used to study
the effects of EGCG on cell viability and proliferation in human lung cancer cells. Quite
surprisingly, we found that EGCG enhanced the

antiproliferative effects of

anthocyanidins and plumbagin, but not the other phytochemicals tested, including
quercetin, withaferin A, curcumin, resveratrol, cucurbitacin B or celastrol. The reasons
can be very complicated because these phytochemicals have been shown to interfere with
many signal transduction pathways and molecular targets (153-162). Anthocyanidins,
plumbagin and EGCG have all been shown to induce ROS production at specific dose
ranges which results, subsequently, in cell death (60, 163, 164).

This supports my

observation that the combination of EGCG with either anthocyandins or plumbagin
results in greater loss of cell viability in lung cancer cells than either phytochemical
alone.
Unexpectedly, EGCG was not found to enhance the antiproliferative effects of all
the tested chemotherapeutics commonly used in lung cancer treatment, including
cisplatin, carboplatin, paclitaxel, docetaxel, doxorubicin, gemcitabine, vinorelbine,
etoposide and topotecan. The reasons remain unknown. Importantly, the antiproliferative

98

effects of cisplatin were significantly enhance when this chemotherapeutic was combined
with EGCG-anthocyanidins. The IC so of cisplatin decreasesd approximately 20 fold
(from 50 IlM to < 3 IlM) in the presence of EGCG-anthocyanidins. Cisplatin is a model
drug in the treatment of lung cancer based on its efficacy as mentioned in the
Introduction.

Therefore, I aimed to further investigate the mechanisms of action of

EGCG-anthocyanidins-cisplatin combination treatment and to determine if these effects
were demonstrable using a xenograft nude mouse model.
Cell cycle analysis in the human lung cancer cells H1299 revealed that cisplatin
induces cell cycle arrest at the G2/M phase.

This observation corresponded to its

significant increase of cyclin Blat the protein level. Additionally, cisplatin was found to
modulate other cell cycle or cell death related proteins including cyclin D 1 and Bcl-2.
Treatment of the cells with EGCG-anthocyanidins did not result in cell cycle arrest at the
tested concentration. Further, the distribution of cells in cell cycle did not differ from
that of the vehicle treatment. It's presumably because EGCG-anthocyanidins nonspecifically inhibit the expression of cell cycle related protein (Figure 5-6). Both cisplatin
and EGCG-anthocyanidins were found to induce cell death at the concentrations tested
(Figure 5-4), and these effects on cell death appear to be additive in these in vitro studies.
The morphological changes and apoptosis induced by cisplatin, EGCG-anthocyanidins
alone or in combination further confirm these findings in flow cytometric analysis.
Using a xenograft nude mouse model, a combination of poly E, anthocyanidins and
cisplatin was found to substantially decrease the tumor volume (73%), while poly E,
anthocyanidins, poly E-anthocyanidins and cisplatin alone group had no observable
effect.

Regrettably, the toxicity caused by the combination treatment was also
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noteworthy. The body weight of the animals in the combination treatment group was
significantly lower than other treatment groups (p<O.Ol).

This observation was

concurrent with a moderate glucose decrease, which correlated to lower diet consumption
in the combination group. Additionally, amylase and lipase levels were also found to be
increased in the combination group, indicating the animals are mobilizing their lipid and
polysaccharides in the body or the possibility of pancreatitis caused by the treatment.
Further, the animals in the combination groups were also observed to be less active
compared with the animals in other groups. Elevated ALT, a liver specific enzyme, and
WBC counts were also observed. AST, alkaline phosphatase and GGT which are not
liver specific, however, were unaffected. These results suggest that the toxicity of the
combination treatment is most likely a result of liver cell damage. The combination
treatment also resulted in damage to the GI tract and disruption of the barrier function of
GI tract causing the pathogens in the digestive tract to enter the blood stream. Pathogens
in the blood can result in an elevated WBC count or possibly increased stress as a result
of the increased handling during the combination treatment lead to the observed increase
in WBC count, or both. In summary, the blood chemistry and blood count correlate with
the toxicity found in the animal study.
Both, efficacy and toxicity were observed only in the cisplatin-poly Eanthocyanidins combination treatment group, suggesting the effects are a result of the
interaction between cisplatin, poly E and anthocyanidins. Although the mechanism(s) of
action through which the combination of these compounds exert their effect are
unknown, indeed effects of cisplatin-poly E-anthocyanidins combination are arguably not
possible to be explained by only one or two mechanisms considering the combination
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mixture could interfere with a multitude of signaling transduction pathways and
molecular targets. A Pubmed literature search on the interaction of cisplatin, green tea
polypheols and anthocyanidins found no similar studies have been conducted. Two
publications were found in which green tea extracts showed protective effects of
cisplatin-induced nephrotoxicity (165, 166). In this study, I investigated the effects of
these drugs on the proteins involved in cell cycle regulation and cell apoptosis. Western
blotting results in cell culture and in the xenograft animal study showed consistent
findings. The combination treatment significantly inhibited the expression of cyclin Dl,
which is almost undetectable in cell culture and dramatically decreased in tumor tissues.
eyclin D 1 is essential for cell proliferation and growth. The extreme low expression of
cyclin Dl will most likely interfere with tumor cell proliferation and growth which was
observable as a therapeutic effect as well as toxicity to normal cell growth which was
reflected in decreased body weight of the treated animals. The expression of Bcl-2, which
is an anti-apoptotic protein, increased after combination treatment both in cell culture and
also in tumor tissue of the animals. Other cell cycle and cell apoptotic related proteins are
also modulated by the combination treatment, which may partially explain the results I
observed. All these results suggest that cisplatin-poly E-anthocyanidins combination has
greater effects in terms of inhibiting cell proliferation and inducing cell apoptosis
compared with individual treatments, thus decreasing the tumor volume. Howerver, it is
apparent that there is no selectivity of this combination treatment in that although it is
efficacious against lung tumor growth, it is concurrently toxic to the host as well. This
conundrum, however, is not uncommon of chemotherapeutic agents and requires a
necessary optimization of treatment protocol for weighted beneficial versus toxic effects.
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In conclusion, my data suggest that combination of EGCG-anthocyanidins may be
effective as adjuvant chemotherapy in combination with cisplatin. However we must pay
special attention to the toxicity caused by the combination treatment. The optimal dosage
of each compound targeting to a moderate efficacy and minimal toxicity needs to be
further studied. Further, the mechanisms of action of this combination therapy need to be
further clarified.
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Table 5-1: Grouping and treatment of the animals.
Cisplatin
PolyE
anthocyanidins
Group
1
2
+, i.p.
3
+, i.p.
4
+, i.p.
+, i.p.
5
+, i.p.
6
+, i.p.
+, i.p.
+, i.p.
7
+, i.p.
+, implant
+, i.p.
+, treatment; -, no treatment; i.p., intraperitoneal injection;
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No. of animals
12
10
10
10
10
10
10

Table 5-2. Blood chemistry test.
5
(cisplatin)

6
(combination)

5.7 ± 0.5
3.5 ± 0.3
2.2 ± 0.2
1.6 ± 0.1
227.5 ±
88.6

4
(poly E+
anthos)
5.3 ±0.2
3.3 ± 0.3
2.1 ± 0.1
1.6 ± 0.2
178.5 ±
42.1

5.8 ± 0.4
3.5 ± 0.5
2.3 ± 0.2
1.5 ± 0.3
242.0 ±
158.2

5.6 ±0.2
3.3 ± 0.1
2.3 ± 0.1
1.4±0.1

33.5 ± 7.9

35.3 ± 7.3

35.0 ± 8.4

64.3 ± 24.1

59.8 ± 19.3
18.0 ± 17.5
0.2 ± 0.1
23.8 ± 2.6
0.4 ± 0.2

70.8 ± 21.0
9.3 ±4.3
0.2 ± 0.1
24.0 ± 3.6
0.4 ± 0.2

68.5 ± 13.5
11.0 ± 12.7
0.2 ± 0.1
22.0 ± 2.9
0.3 ± 0.1

69.3 ± 22.2
9.0 ± 2.6
0.2 ± 0.0
31.5±3.1
0.4 ± 0.2

82.5 ± 37.5
12.8±1.8
102.8 ±
27.4
9.8 ±0.2
3.5 ±0.2
147.3 ±
11.0
6.9 ±4.8

86.3 ± 45.9
13.9 ± 1.5

82.5 ± 34.3
11.2 ± 1.4
137.0 ±
61.4
10.3 ± 0.3
3.1 ±0.3

105.0 ± 62.3
10.9 ± 1.9
77.3 ± 18.4
7.2 ± 4.4
2.9 ± 0.3

152.0 ± 6.7
9.7 ± 0.9

157.5 ± 7.7
10.2 ± 1.4

16.0 ± 2.2

15.8 ± 1.7

107.0 ± 3.5
140.0 ±
10.8

109.5 ± 4.4

Group

1
(veh.)

2
(poly E)

3
(anthos)

Total Protein
Albumin
Globulin
A1G Ratio

6.0 ±0.3
3.7 ± 0.3
2.3 ± 0.3
1.7 ± 0.3
216.3 ±
53.3

5.4 ± 0.2
3.2 ± 0.1
2.2 ±0.3
1.5 ± 0.2
185.0 ±
68.1
39.3 ±
13.4
79.8 ±
17.0
8.3 ± 2.9
0.2 ± 0.1
25.3 ± 2.2
0.3 ± 0.1
95.0 ±
38.9
13.6 ± 0.9
75.0 ±
25.9
9.2 ± 0.5
3.4 ± 0.2
149.0 ±
12.1
7.7 ± 2.8
22.0±
10.0
105.8 ±
7.5
127.0 ±
3.2
112.3 ±
14.5
623.0 ±
108.1
85.5 ±
23.4
630.5 ±
422.5

AST (SGOT)
ALT (SGPT)
Alkaline
phosphatase
GGT
Total Bilirubin
BUN
Creatinine
BUN/Creatinine
Ratio
Phosphorus

36.5 ± 6.4
57.8 ± 18.6
15.8 ± 8.8
0.2 ± 0.1
28.0 ± 2.8
0.4 ± 0.1
87.5 ± 35.7
15.8 ± 1.2

Glucose
Calcium
Magnesium

94.5 ± 50.9
10.1 ± 0.3
3.9 ±0.2

Sodium
Potassium

154.8 ± 9.4
10.9 ± 1.0

Na/K Ratio

14.3 ± 1.3

Chloride

107.5
146.5
10.2
134.5
41.4
691.0
91.3

Cholesterol
Triglyceride
Amylase
Lipase
CPK

± 6.6
±
±
±

93.8 ± 18.2
816.0 ±
492.0

31.5 ± 20.2
108.0 ± 8.0
128.8 ±
20.6

82.5 ± 35.2
9.6 ± 0.4
3.6 ± 0.1
151.0±
11.6
7.1 ± 4.9
30.5 ± 18.1
104.8 ±
10.0

97.3 ± 11.2
644.3 ±
102.5

129.5 ± 7.8
104.8 ±
36.1
700.8 ±
112.5

116.5 ± 5.7
758.8 ±
83.8

90.0 ± 9.1
1088.5 ±
655.8

98.0 ± 11.2
607.5 ±
203.3

98.8 ± 8.4
1358.3 ±
1316.6
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234.5 ± 43.9

152.0 ± 17.7
92.0 ± 31.3
1459.8 ±
918.2
660.3 ±
1125.2
522.8 ± 131.4

Table 5-3. Blood cell counts.
Group

WBC
RBC
HOB
HCT
MCV
MCH
MCHC

1
(veh.)

2
(poly E)

3
(anthos)

2.3 ± 1.5
7.3 ± 0.5
11.9 ± 0.5
39.8 ± 3.0
56.0 ± 2.6
16.5 ± 0.4
29.7 ± 1.2

1.7 ± 0.5

3.6 ±2.8
7.3 ±0.8
12.4 ± 0.8
38.3 ± 6.9
56.7 ± 1.5
17.2 ± 0.9
30.7 ± 2.1

(poly E+
anthos)
4.7 ± 1.3
7.8 ± 0.3
13.0±0.4
43.5 ± 2.9
55.8 ± 1.3
16.6 ± 0.5
29.8 ± 1.5

686.3 ±
442.4
2559.0 ±
2068.4
322.0 ±
366.5

33.7 ± 2.5

5
(cisplatin)

6
(combination)

3.5 ± 3.1
7.7±0.1
13.1 ± 0.4
36.3 ± 7.3
55.5 ± 0.7
17.0±0.1
30.5 ± 0.7

6.0 ± 1.3
7.0 ±0.2
11.9 ± 0.3
38.3 ± 1.7
54.8 ± 2.4
17.0 ± 0.4
31.3±1.0

1448.8 ±
784.0
2968.8 ±
798.0
240.0 ±
232.4

534.8 ±
421.7
2594.3 ±
2430.5
343.5 ±
385.0

2018.0 ±
1101.9
3591.5 ±
707.9

43.0 ± 26.3
14.8 ± 29.5

67.5 ± 52.4
0.0 ± 0.0

38.3 ± 28.1
14.3 ± 28.5

0.0 ± 0.0
0.0 ± 0.0

1001.0 ±
325.7

1105.0 ±
189.4

925.0 ±
240.4

1199.5 ±
301.3

20.3 ± 8.5
71.0 ± 7.7
7.0 ± 4.8
1.5 ± 0.6
0.3 ±0.5

29.8 ± 11.3
63.5 ± 7.9
5.5 ±4.8
1.3 ± 1.0
0.0 ± 0.0

24.5 ± 17.6
67.0 ± 12.7
7.0 ± 5.3
1.3 ± 0.5
0.3 ± 0.5

32.8 ± 12.1
60.8 ± 10.2
6.5 ± 3.0
0.0 ±O.O
0.0 ±O.O

4

Differential
Neutrophils
Lymphocytes
Monocytes
Eosinophils
Basophils
Platelet Estimate

452.8 ±
263.2
1601.3 ±
1070.4
234.8 ±
169.1
28.8 ± 9.1
7.5 ± 15.0

Platelet Count

1101.3 ±
185.8

Differential {% 1
Neutrophils
Lymphocytes
Monocytes
Eosinophils
Basorhils

20.5 ± 7.2
68.0 ± 4.2
9.8 ± 3.6
1.5 ± 0.6
0.3 ± 0.5

640.5 ±
119.5
864.0 ±
326.6
102.0 ±
112.0
43.5 ±
37.1
0.0 ± 0.0

40.0 ± 6.6
52.0 ± 6.2
5.3 ±4.3
2.8 ± 2.5
0.0 ±O.O
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390.5 ± 193.6
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Fig. 5-1. MTT assay of anthocyanidins (delphinidin, cyanidin, malvidin, peonidin,
petunidin with equal molar concentration) at the presence/absence of EGCG.
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Fig. 5-2. MTT assay of cisplatin at the presence/absence of EGCG and anthocyanidins
(delphinidin, cyanidin, malvidin, peonidin, petunidin with equal molar concentration).
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Fig. 5-3. The effects of vehicle, cisplatin, EGCG+anthocyanidins alone or in combination
on cell cycle. A. vehicle; B. 10 !!M of cisplatin; C. 10 !!M of EGCG- anthocyanidins
(delphinidin, cyanidin, malvidin, peonidin, petunidin with equal molar concentration); D.
10 !!M of cisplatin plus 10 !!M of EGCG-anthocyanidins.
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Fig. 5-4. The effects of vehicle, cisplatin, EGCG-anthocyanidins alone or in combination
on cell apoptosis. A. vehicle; B. 25 flM of cisplatin; C. 10 flM of EGCG- anthocyanidins
(delphinidin, cyanidin, malvidin, peonidin, petunidin with equal molar concentration); D.
25 flM of cisplatin plus 10 flM of EGCG-anthocyanidins.
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Fig. 5-5. Ethidium bromide/acridine orange staining of the cells treated with vehicle,
cisplatin, EGCG-anthocyanidins alone or in combination. A. vehicle; B. 7.5 !!M of
cisplatin; C. 7.5 !!M ofEGCG-anthocyanidins (delphinidin, cyanidin, malvidin, peonidin,
petunidin with equal molar concentration); D. 7.5 !!M of cisplatin plus 7.5 !!M of EGCGanthocyanidins.
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Fig. 5-6. Protein expression of H1299 lung cancer cells treated with treated with vehicle,
cisplatin, EGCG-anthocyanidins alone or in combination. A. vehicle; B. 7.5 !AM of
cisplatin; C. 7.5 !AM of EGCG-anthocyanidins (delphinidin, cyanidin, malvidin, peonidin,
petunidin with equal molar concentration); D. 7.5 !AM of cisplatin plus 7.5 !AM of EGCGanthocyanidins.

110

800

-

700

--+- veh.

C ")

<

E

- - poly E i.p.
anthos i.p.
__ poly E+anthos i.p.
__ cisplatin i .p.
--+- cisplatin+poly E+anthos i.p.
-+- cisplatin+anthos i.p.+poly E implant

600

----b-

.§. 500
CI)

§ 400
0

>
10.

300

0

E
j

***

200

~

100
0
0

3

2

4

5

Week
.Fig. 5-7. Effects of treatments (vehicle, poly E alone, anthocyanidins alone, poly E +
anthocyanidins alone, cisplatin alone, cisplatin + poly E + anthocyanidins i.p. and
cisplatin+anthocyanidins i.p. combined with poly E implant) on tumor volume in
xenograft nude mouse model. Standard deviation coefficients range from 0.13 to 0.77,
with an average of 0.43 and a median of 0.45 (*p<0.05, **p<O.Ol, ** *p<O.OOl).
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Fig. 5-8. Pictures of nude mice treated with vehicle, poly E alone, anthocyanidins alone,
poly E + anthocyanidins alone, cisplatin alone, cisplatin+poly E+anthocyanidins by i.p.
and cisplatin+anthocyanidins i.p. combined with poly E implant.
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Fig. 5-10. HE staining of animal skins. Upper panel: vehicle treated group; lower panel:

cisplatin+poly E+anthocyanidins i.p. group.
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Fig. 5-11. Protein expression in the tumor tissues. 1-6 represents the group number.
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CHAPTER VI: SUMMARY

Green tea is one of the most popular drinks in the world. It's drawing increasing
attention because of its potential chemopreventive effects. Green tea polyphenols (GTPs),
induding EGCG, ECG, EGC and EC are believed to be the active components, in which
EGCG is the most active catechin.
Although numerous in vitro studies have demonstrated the anti-cancer effects of
GTPs, epidemiological and clinic data showed mixed results. One major reason is due to
lack of oral bioavailability of GTPs limits their efficacy in vivo.
In our laboratory, we developed a novel delivery system

In

which GTPs are

uniformly embedded with a polymer matrix to provide sustained release of GTPs. I
hypothesized that administration of these GTPs via subcutaneous polymeric implants will
circumvent the problem of limited bioavailability of GTPs and lower the effective dose
compared to the traditional oral route.
The release profile of these implants was investigated both in vitro and in vivo
(Chapter 11). The results showed that GTPs were released from these PCL implants in a
continuous fashion and the in vitro and in vivo release follows a similar fashion. More
importantly, GTPs remain stable during preparation of the implants and in vivo within the
time duration tested (Chapter IV), although they are not stable at alkaline or near neutral
condition once released from implants (Chapter II).
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In animal study, polyphenon E (poly E), a standardized green tea extract, was
administered by PCL implants grafted subcutaneously or via the drinking water. When
challenged by continuous low dose of benzo[a]pyrene (BP) via subcutaneous polymeric
implants, the GTP-polymeric implants showed a significant reduction of BP-induced
DNA adducts; however, only a modest but insignificant reduction occurred when GTPs
were administered via the drinking water. The implant delivery system also showed
significant reduction of the known BP diolepoxide-derived DNA adduct after 4 weeks.
Notably, the total dose of poly E administered was> IOO-fold lower in the implant group
than the drinking water group (Chapter IV). This supports my hypothesis that sustained
systemic delivery of poly E significantly reduced BP-induced DNA adducts by
overcoming oral bioavailability issue and that the effective dose of poly E was
substantially lower than oral delivery.
Mechanistic studies of poly E, at submicromolar plasma levels achieved in this
study, suggest that its efficacy at inhibiting BP-induced DNA damage was not a result of
modulation of metabolic or DNA repair pathways (Chapter IV) but from direct
scavenging of the electrophillic metabolites, which has been detailed in my microsomal
studies and LCIMS study in Chapter III.

In the microsomal experiments, BP was

incubated with rat liver micro somes and DNA in the presence of the green tea catechins
or vehicle. DNA adduct formation was analyzed. The inhibitory activity of the catechins
was in the following descending order: epigallocatechin gallate > epicatechin gallate >
epigallocatechin > epicatechin, suggesting a correlation between the number of adjacent
aromatic hydroxyl groups in the molecular structure and their potencies. To determine if
the activity of these compounds was due to direct interaction of phenolic groups with
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electrophilic metabolite(s) ofBP, DNA was incubated with anti-benzo[a]pyrene-7,8-diol9,1O-epoxide (anti-BPDE). Significant inhibition of DNA adduct formation was found in
the same order as shown above. Data from ESI/MS and LCIMS study confirmed and
characterized the anti-BPDE-EGCG adduct. The hydroxyl groups on the B ring or Dring
of EGCG molecule can interact with anti-BPDE. My data demonstrate that green tea
catechins are highly effective in inhibiting BP-DNA adduct formation at least, in part,
due to direct interaction of adjacent hydroxyl groups in their structures, and that the
activity is higher with an increasing number of functional hydroxyl groups.
My second hypothesis is that adjuvant treatment of GTPs with a standard cancer
chemotherapeutic agent will enhance efficacy of the drug because GTPs bear some
distinct mechanisms of action which are different from other drugs.
To test the second hypothesis, I investigated the combined effect of EGCG and the
berry anthocyanidins (EGCG-ANTHOS) alone and in combination with a common
chemotherapeutic drug cisplatin on lung cancer Hl299 cell using the MTT assay and also
the combined effect of poly E, bilberry extract and cisplatin in xenograft nude mouse
model. In vitro, the antiproliferative activity of EGCG-ANTHOS was found to be better
than ANTHOS and EGCG alone. The combination of EGCG-ANTHOS and cisplatin
increase the efficacy of cisplatin. Flow cytometric analysis for cell cycle distribution and
apoptosis revealed cell cycle arrest and enhanced apoptosis induced by the combination
mixture. Western blot analysis for the involved molecular targets showed that selected
proteins (cyclin Dl, BI, p2I, PCNA, Bcl-2, PARP, etc.) associated with either cell cycle
or apoptosis were more significantly modulated by the combination. In vivo, the
combined effect of poly E-anthocyanidins and cisplatin caused significant inhibition on
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tumor volume (73% reduction), which was significantly better than poly E,
anthocyanidins and cisplatin alone groups, all of which do not show significant effect.
However, concurrent with the efficacy from the combination treatment, toxicity is also
obvious, manifested as the less activity of animals, body weight, elevated ALT and WBC
count as well as the histological finding in skin. Clearly, no one generalized mechanism
of action can explain the effects including both the efficacy and the toxicity effects. I
investigated the effects of these compounds on the expression of cell cycle and cell
apoptosis related proteins and the results showed the enhanced expression on some
proteins including cyclin Dl, Bcl-2 etc. which may explain the dramatic effects of the
combination treatment in one respect. Taken together, my data suggest that EGCGANTHOS may be effective as adjuvant chemotherapy in combination with suboptimal
doses of cisplatin. However, the potential toxicity effect of the combination treatment
should be further addressed.

119

CHAPTER VII: IMPACT OF THE RESEARCH FINDINGS AND FUTURE
PERSPECTIVES

We developed subcutaneous biodegradable polymeric implants which may provide
a viable sustained release system for chemopreventive/chemotherapeutic agents with
poor oral bioavailability. Chemopreventives are generally administered orally. On the
other hand chemotherapeutic agents due to their poor bioavailability are usually given
intravenously. For cancer patients, chemotherapy needs to be performed during a
relatively long period of time. Therefore, oral administration appears to be burdensome
and not cost-effective. Through this sustained systemic delivery system, not only can
enhance the bioavailability but also be cost-effective. Further, patients with cancer might
have a better compliance. One important thing for the success of cancer treatment is to
prevent the growth of residual cancer cells after the surgery locally as well as
systemically. Polymeric implants containing chemotherapeutic drugs will be a good
choice to kill the possible residual cancer cells after surgery and also the floating cancer
cells in the body. One approach is to leave the polymeric implants containing
chemotherapeutic drugs at the surgical site, which might have residual cancer cells left
before closing the wound. In that respect, no separate surgery needs to be done and the
cost will be minimal. Before this sustained delivery system can be used in cancer
patients, more work need to be performed. First, the release profile of these polymeric

120

implants is not optimized. Theoretically, a zero-order or near zero-order release profile
will be more attractive. Second, an acceptable toxicity profile including both systemic
and local toxicity should be the minimal requirement before any clinical application.
Third, the dose of drugs can be precisely controlled for the purpose of efficacy and
toxicity.
I also illustrated a new mechanism of action of green tea polyphenols, i.e. GTPs
inhibit BP-induced DNA adduct formation through direct quenching of the electrophilic
metabolites of BP, which partially closed the gap between the knowledge of
chemopreventive effects of GTPs and the way they might work. It may help the
mechanism studies of many other phytochemicals. Some phytochemicals bearing similar
molecular structure may work in the same way, which will be a direction for future
studies.
In addition, I found the synergistic effects of GTPs, anthocyanidins and cisplatin,
suggesting the possibility of using GTPs and anthocyanidins as adjuvant treatment in
combination with cisplatin. However, more studies need to be performed in order to
figure out the components responding to the efficacy as well as the toxicity. The purpose
of these studies is to find a more rational combination of these reagents which improves
the response rate and/or reduces toxicity. The ultimate goal will be a clinical application.
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APPENDIX I: ABBREVIATIONS

SGG

pentagalloylglucose

9-0H-BPE

9-0H-benzo[a]pyrene-4,5-epoxide

ALT

alanine transaminase

anti-BPDE

anti-benzo[a ]pyrene-7 ,8-diol-9, 10-epoxide

AST

aspartate transaminase

BP

benzo[a]pyrene

BUN

blood urea nitrogen

CD

cyclodextrin

Cmax

maximum plasma concentration

CPK

creatine phosphokinase

Cr

creatinine

CYPs

cytochrome P450s

DMSO

dimethyl sulphoxide

EC

(-)-epicatechin

ECG

(-)-epicatechin gallate

EDTA

ethylenediaminetetraacetic acid

EGC

(-)-epigallocatechin

EGCG

(-)-epigallocatechin gallate

EGF

epidermal growth factor
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FBS

fetal bovine serum

FDA

Food and Drug Administration

FGF2

fibroblast growth factor 2

G6PDH

glucose-6-phosphate dehydrogenase

GGT

gamma-glutamyltransferase

GTP60

a green tea extract preparation containing 60% catechins

GTPs

green tea polyphenols

HCT

hematocrit

HGB

hemoglobin

HGF

hepatocyte growth factor

HPLC

high performance liquid chromatography

MCH

mean corpuscular hemoglobin

MCHC

mean corpuscular hemoglobin concentration

MCV

mean corpuscular volume

MN/SPD

micrococcal nuclease and spleen phosphodiesterase

MTT

3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide

NDEA

N-nitrosodiethylamine

NER

nucleotide excision repair

NNK

4-(methylnitrosamino)- 1 -(3-pyridyl)- 1- butanone

PIS

poly (epsilon-caprolactone) with molecular weight of 15,000

P6S

poly (epsilon-caprolactone) with molecular weight of 65,000

PAHs

polycyclic aromatic hydrocarbons

PBS

phosphate buffered saline
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PCL

poly (epsilon-caprolactone)

PEG

polyethylene glycol

polyE

polyphenon E

qPCR

real-time quantitative polymerase chain reaction

LCIMS

liquid chromatography-mass spectrometry

RBC

red blood cell

ROS

reactive oxygen species

SDS

sodium dodecyl sulfate

TA

tannic acid

WBC

white blood cell
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